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CHAPTER 1. INTRODUCTION 
Background 
 Appropriate design, implementation, and analysis of any study design, 
experimental or observational, are paramount to making accurate and valid etiologic or 
associative inference. In the absence of thoughtful design and reporting, studies may suggest a 
spurious relationship or be misclassified and valid information lost. For the former, this has 
potentially serious implications in human or veterinary health. If underreported or inaccurately 
designed studies suggested an association between a risk factor and disease outcome that did not 
actually exist, substantial resources may be wasted in an attempt to manage the wrong disease 
cause. As a result, individuals would remain ill as additional cases develop and the population 
burden rises. Studies that are misclassified (erroneously indexed in reference databases) as a 
result of being incorrectly titled have major implications for the conducting of systematic 
reviews and meta-analyses. For example, if a systematic review were designed in such a way to 
include only trials that randomize study subjects to treatment, trials in the searched reference 
databases that successfully randomized during study implementation but failed to suitably report 
the process in the manuscript would be wrongly excluded. Consequently, potentially valuable 
data would be lost from a meta-analysis and the resulting summary effect may be less accurate. It 
is thus of the utmost importance that experimental and observational research is not only 
designed properly but reported accurately as well. 
In recent years there has been a strong push in both human and veterinary research to 
establish guidelines for the reporting of research. For example, in human research, guidelines 
have been established and adopted by a number of peer-reviewed journals covering randomized 
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controlled trials (RCT) (Schulz et al., 2010), systematic reviews (Moher et al., 2009), and 
observational studies (von Elm et al., 2007). Similarly in the veterinary science there has been 
increased interest in adopting or modifying these same principles of reporting guidelines to 
ensure accuracy and reproducibility (O'Connor, 2010; Sargeant and O'Connor, 2014b). As of 
today, guidelines have been established and adopted in numerous veterinary journals for the 
reporting of RCTs in livestock and food safety (O'Connor et al., 2010). In the veterinary sciences 
when design specific guidelines are unavailable, some diligent researchers have provided in-
depth design descriptions from inception through analysis. For example, a recent series of 
manuscripts covered the application of systematic reviews, a relatively new or uncommon design 
strategy in the veterinary science (O'Connor et al., 2014a; O'Connor et al., 2014b; Sargeant and 
O'Connor, 2014a). It is likely that additional design-specific guidelines in the veterinary science 
will be considered as more thorough examinations of the quality of the literature are conducted. 
Objectives 
The aim of this thesis is to examine epidemiological study designs in the veterinary 
science for study design considerations and the reporting of study characteristics. This was 
executed using two approaches for two study designs: 1) a survey of veterinary case-control 
studies and 2) an investigation of RCTs within the framework of a systematic review and meta-
analysis. 
Thesis Organization 
The format of this thesis is based on the use of journal papers as chapters. The second 
chapter contains a literature review of hospital-based case-control studies in the veterinary 
science. Chapter three is a survey of the veterinary literature for author designated case-control 
studies. Both the second and third chapters will be submitted to the Journal of Veterinary 
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Internal Medicine for publication. Chapter three comprises a systematic review and meta-
analysis for the treatment of infectious bovine keratoconjunctivitis. This chapter has been 
submitted and accepted for publication in Animal Health Research Reviews (Cullen et al., In 
press). Co-author contributions to these manuscripts will be described on the first page of each 
chapter. Finally, the last chapter contains the thesis conclusions and recommendations for future 
research.  
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CHAPTER 2. A REVIEW OF THE APPROACH TO CONDUCTING HOSPITAL-
BASED CASE-CONTROL STUDIES IN VETERINARY SETTINGS 
A paper to be submitted to the Journal of Veterinary Internal Medicine 
Purpose and Scope 
Many designs can be used to investigate disease etiology, and these can broadly 
be classified into experimental or observational. The three most common observational 
designs are cross-sectional, cohort, and case-control. Of the three observational designs, 
the case-control design is often considered simple to design and the most cost effective 
for investigating disease etiology. The inexpensive nature is related to financial and time 
costs. As a result, clinicians wanting to examine an association between a disease or 
outcome of interest and an exposure often conduct a case-control study. Despite, its 
popularity, the case-control study is also considered of lesser value when estimating an 
exposure-disease association, as illustrated by its lower location on many statistical 
evidence pyramids. It is likely true that case-control studies are cheaper to conduct than 
cohort studies, however the common perceptions of simplicity and evidentiary value can 
be false. The view that case-control studies are simple to design can lead to important 
design considerations ignored (if not unknown) and misinterpretation of the results. 
Moreover when properly designed (and comprehensively reported), a case-control study 
may be of more evidentiary value than traditionally held. The purpose of this review is 
therefore to help clinicians better understand this important design. The aim is to describe 
the proper planning, necessary design descriptions, and suitable interpretation of the 
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results for case-control studies using hospital-based records. We focus on hospital-based 
designs as these are commonly used in veterinary settings.  
This review is targeted at companion animal clinicians interested in studying 
disease etiology at the individual level but will be applicable to any clinician, companion 
or food producing animal, planning to conduct a hospital-based case-control study based 
on hospital records. 
The review will include a general description of the observational designs, 
compelling reasons for choosing a case-control design, appropriate selection of cases and 
controls, methods for controlling common biases, and proper interpretation of the 
associations observed. Additionally, when possible, the discussion will be limited to 
dichotomous or nominal variables. Discussion of group level (e.g. herd, pen, or liter) case 
and control selection, and interpretation will be limited.  
What Constitutes a Case-Control Design? 
Before describing the defining features of the case-control design, it is worth 
briefly relating how this design fits within the framework of the other analytic (or 
explanatory) observational study designs. The primary purpose of these observational 
study designs is to investigate disease etiology or the causal association between an 
exposure and disease with or without a temporal component. Note that exposure and risk 
factor may be used interchangeably. 
Arguably, the simplest observational study design, the cross-sectional study is 
often used by veterinary clinicians to examine factors associated with disease prevalence 
within a population (Dohoo et al., 2009). The cross-sectional design is suited to this 
purpose because disease and exposure information are collected from a population at a 
 7 
single point in time. Disease prevalence may then be compared between different 
exposure subgroups. Cross-sectional studies can be conducted quickly and the 
investigator may examine multiple exposures and diseases simultaneously (Morgenstern 
and Thomas, 1993). Cross-sectional studies are however limited in making causal 
inference as it difficult to distinguish cause from effect (i.e. exposure leads to disease). 
This is due to exposure and disease ascertainment occurring at a single point in time 
(Mann, 2003). It is possible that researchers actually identify an association between 
exposures and survival, rather than disease, so the inference about etiology based on 
cross-sectional studies should be carefully considered.  
Compared to the cross-sectional design, the cohort study explicitly employs a 
temporal component. This temporal component is in fact one of defining features of the 
cohort design: the study group or cohort, sampled based on exposure status, is followed 
over time for the development of an outcome of interest [see Grimes and Schulz (2002) 
for a concise review or (Rothman and Greenland, 1998)]. Dekkers et al. (2012) recently 
proposed that in addition to subjects sampled on exposure and followed forward in time, 
the ability to calculate an absolute risk, which may be done using a single group, is a 
defining feature of the cohort design. Thus a traditional cohort design consists of one or 
more study groups based on an exposure of interest that are followed over time to 
outcome. Follow-up from exposure to outcome may be conducted prospectively or 
retrospectively using historical records (Euser et al., 2009). It should be noted the terms 
“prospective” and “retrospective” are not ideal and have historically been a source of 
confusion (Vandenbroucke, 1991). Ideally, the source population from which the study 
groups are derived should be the same (e.g. veterinary records from a single teaching 
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hospital). Additional information on the design characteristics, implementation, and 
analysis may be found elsewhere (Breslow and Day, 1987; Prentice, 1995; Rothman and 
Greenland, 1998; Dohoo et al., 2009). 
Where the cohort design is concerned with selecting and comparing study groups 
based on exposure status, the case-control design is based on the selection of study 
groups or individuals with or without the outcome of interest [see Schulz and Grimes 
(2002) for a general review]. Individuals with the outcome are referred to as cases and 
individuals without the outcome are referred to as controls. The previous exposure status 
(i.e. exposure data or risk factors ascertained prior to development of the outcome) of 
“cases” is then compared to the previous exposure status of individuals of “non-cases” or 
“controls”. Most importantly, the control group should be randomly selected in such a 
way that the exposure distribution is representative of the exposure distribution in the 
source population (Miettinen, 1985a; Wacholder et al., 1992b). There are multiple 
potential source populations from which the cases and controls may be drawn, and this 
review will focus specifically on hospital-based records. The hospital-based source 
population and the representative nature of the control series will be discussed in more 
detail below. 
Sometimes, investigators think of the terms “cases”, “diseased animals” and “sick 
animals” as synonyms, while also thinking of the term “controls” as synonymous with 
“non-diseased” or “healthy”. Therefore, any study with diseased and non-diseased 
animals is a case-control study. However, this approach to naming is incorrect and 
produces much of the confusion observed in case-control studies. The true defining 
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feature of a case control study is selection based on the outcome, not the use of healthy 
and non-healthy animals, as we will see. 
Why Choose a Case-Control Design to Investigate Etiology? 
Before planning and implementation of a case-control study, the first question a 
clinician should ask is why choose the case-control as opposed to the other observational 
or experimental design choices. The most common answer for choosing the case-control 
design is the relative efficiency in terms of money and time. 
One of the main motivations for choosing a case-control study, as opposed to a 
cohort, is the savings in money for the researcher particularly for a hospital-based case-
control study. When hospital-records are used to identify the cases, ideally well-
maintained databases with detailed records can be queried to identify all patients 
diagnosed with a disease of interest. Similarly, controls are identified from the same 
databases and disease etiology may be investigated using proper analysis at relative low 
cost. If cases (and controls) are recruited from a population at large without hospital 
records, the cost required identifying a suitable number of patients might be significantly 
higher. Alternatively, if a cohort study (hospital or population based) is designed to 
investigate disease etiology, patients with the risk factor thought to cause disease, will 
need to be followed over time for development of the disease either through additional 
record searching or through patient owner contact. 
Case-control studies are relatively more efficient than cohorts in terms of time 
required for the data collection phase. This is due to the defining feature of the case-
control design where subjects are enrolled based on outcome, and only after enrollment is 
the exposure status determined. Thus the follow-up time for outcome incidence as needed 
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in cohort studies is not required. For the clinician using available hospital-based records, 
this timesaving could be significant compared to a cohort study. 
Of course such efficiency must be balanced against the accuracy and validity of 
the exposure-disease association obtained from a case control study. The trade off 
between the case-control design efficiency and accuracy and validity of the exposure-
disease association measure is a common concern amongst clinicians and 
epidemiologists. The validity and accuracy concerns are related to some common sources 
of bias associated with the case-control design (discussed in more detail below) (Sackett, 
1979). Wacholder et al. (1992a) reviews how case-control design choices related to 
aspects of efficiency are often times at odds with design principles that reduce these 
biases. As a result, case-control designs are often considered of lesser inferential value. 
Indeed, a hierarchical ranking of study designs places case-control in an the intermediate 
region (Phillips et al., 2001). Concato et al. (2000) compared meta-analyses of 
randomized controlled trials (RCT) and meta-analyses of cohort or case-control studies 
for five different human clinical topics. Their results suggested that when well designed, 
either cohort or case-control studies resulted in highly similar effect estimates compared 
to RCTs assessing the same intervention. For a review on the inclusion of observational 
studies (as related to their inherent biases) in meta-analyses for animal disease outcomes 
see O'Connor and Sargeant (2014). 
To summarize, a clinician wishing to assess disease etiology should consider a 
case-control design if time and money are constraining factors. The trade off between 
efficiency, accuracy and validity should be carefully considered as well. The following 
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section will discuss under what conditions the case-control design can be employed to 
maximize this efficiency. 
When is the Case-Control Design the “Best” Option? 
The case-control design is typically the most efficient design option for 
investigating the etiology of a particular disease outcome under two scenarios, the disease 
is rare or there is a long latency period for disease onset. 
When the outcome is rare, identifying individuals based on the outcome is an 
advantage compared to identification based on exposure. Rare in this case means the 
incidence of the particular outcome is uncommon in the source population (e.g. patient 
records at a veterinary referral hospital) from which the study population is drawn. 
Consider a situation of attempting a cohort study compared to a case-control where the 
outcome of interest in rare. Since the cohort design selects study groups based on an 
exposure of interest, the cohort would potentially require a much larger study population 
in order to identify individuals experiencing the outcome over time. However as the case-
control study selects individuals based on the outcome, it is a much more efficient design 
choice to assess the exposure-disease association in this situation. Put another way, if the 
cost of identifying exposed and diseased individuals is equal for both the case-control and 
cohort, the most efficient design will identify a number of exposed individuals with less 
cost compared to the other option. Therefore when the outcome is rare compared to the 
proportion of exposed individuals within the study population (i.e. fewer animals with 
disease than animals exposed), it is more efficient to identify individuals that have the 
outcome and are exposed among the case group (case-control design) compared to 
identifying the same individuals among an exposed group (cohort design) (Wacholder, 
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1995). For example, a case-control design was used to investigate different 
endocrinopathies as risk factors for development of the uncommon outcome gall bladder 
mucoceles in dogs (Mesich et al., 2009). 
The second situation, in which the case-control design is potentially more 
efficient than a cohort, is one in which the outcome of interest has a long latency period. 
Similar to the above reasons, by selecting on the outcome with the case-control study, 
long follow-up times are not required in order to observe the outcome of interest among 
the study groups. A cohort study examining an exposure-outcome association where the 
outcome has a long latency period would require a longer follow-up time in order to 
observe subjects with the outcome. Thus a case-control design would be more efficient in 
this situation. Sallander et al. (2012) recently utilized a case-control design to 
demonstrate that obese cats were more likely to have diabetes mellitus (long latency 
period) compared to non-obese cats. This study might have been much more inefficient if 
a cohort design had been chosen by the researchers, where obese non-diabetic cats and 
normal-weight non-diabetic cats would have been followed for years to determine the 
incidence of diabetes development in each group. 
Additionally, when exposure ascertainment is expensive compared to diagnosing 
the outcome, the case-control may be the cheaper option. For example, Minozzi et al. 
(2010) examined the potential genetic risk factors for Johne’s susceptibility. Here the 
outcome (Johne’s disease) was assessed during routine screening via an enzyme-linked 
immunosorbent assay (ELISA) and the exposure (genomic features) was measured on a 
subset of serologically positive and negative animals. Clearly the cost of genomic 
analyses is far more expensive than ELISA per sample. It would be costly to measure the 
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exposure status of a large number of individuals for which only a fraction develop the 
outcome (as with a cohort design) compared to a subset of cases and non-cases as with a 
case-control study. 
How to Select Cases and Controls? 
The following section discusses important considerations for the selection of 
cases (individuals with the outcome of interest) and controls (individuals without the 
outcome): the source population for cases and controls, the “nature” of the cases, number 
of control groups, size of the control group, source population type, and the timing of 
control selection.   
Source population of cases and controls 
The source population is the population from which the cases and controls arise. 
This population may be a primary or secondary study base. A primary study base is one 
in which the source population is clearly defined (or enumerated) for example by 
geographic region during a specific time period such as a farm with accurate record 
keeping (Miettinen, 1985b; Miettinen, 1985a; Dohoo et al., 2009). This may also be 
referred to as a population-based case-control study (Wacholder et al., 1992b). The 
advantage of designing a population-based study is the source population from which the 
controls are drawn is guaranteed to be the same as that of the cases. The main concern 
with employing a primary case base in a case-control design is the potential for 
incomplete case identification (Miettinen, 1985b). This population base is not discussed 
further because as the focus is on hospital based case control studies, which are 
considered a secondary base. 
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 If a referral hospital (the focus of this review) or disease registry is employed to 
identify cases and controls over a specific time period, it is considered a secondary study 
base (Miettinen, 1985b; Miettinen, 1985a). The primary advantage of using a secondary 
study base such as a referral hospital, is the case series (the cases in a case-control study) 
is complete, i.e. incomplete case identification is less likely to occur as with a primary 
study base (Wacholder et al., 1992a). Complete case identification is a result of using 
hospital databases to identify potential cases as opposed to attempting to identify patients 
with the outcome of interest from population-based study. Complete case ascertainment 
will increase effect measure precision and decrease case selection influenced by the 
exposure of interest or disease severity (Wacholder, 1995). For additional information 
regarding other sources of controls see Wacholder et al. (1992b). 
The difference between employing a primary or secondary study base is an 
important consideration. Miettinen (1985a) described the distinction between primary and 
secondary bases as related to the order in which cases or the base population is defined. 
When the base is defined before or independent of the cases it is a primary study base. 
When the base is defined secondary to cases it is a secondary study base (i.e. the 
population the cases likely came from). It is this distinction that leads to a fundamental 
issue when using hospital records (or any other secondary study base) for a case-control 
study, what is the study population (the case base) from which suitable controls may be 
identified?  Recall that the control series should be selected with an exposure distribution 
representative of the non-diseased in the source population from which the cases were 
identified. The fact that the source population is “unknown” may create the potential to 
get that wrong.  
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When using hospital-based records to select controls, the base population may be 
difficult to define, as it is not explicitly based on a geographical region. Instead, the base 
population consists of patient owners that would potentially visit or be referred to the 
hospital and thus could have been considered as part of the case series if the disease or 
outcome of interest had occurred (Miettinen, 1985b). By identifying the case series via 
hospital records, it is a reasonable assumption that other patient owners without the 
outcome of interest at the same hospital would be members of the same secondary base. 
These patient owners may therefore be considered for the control group, denoted hospital 
controls. This is in fact one of the main advantages of using a hospital-based secondary 
study base to identify controls (Miettinen, 1985b; Wacholder et al., 1992a). 
Hospital controls may be healthy animals (e.g. hospital staff owned animals 
volunteered for inclusion in the study) or they may be affected by another disease. 
Employing animals with other diseases could present a potential issue if distribution of 
exposure in the “sick” control group is not be representative of the exposure distribution 
in the case base, the fundamental comparison of the case-control design (Miettinen, 
1985b). To avoid this potential pitfall, two assumptions must be made: 1) for the “sick” 
controls, the outcome that caused hospital admittance must be unrelated to the exposure 
of interest, and 2) admitted cases could have been enrolled as “sick” controls and vice 
versa (Wacholder et al., 1992a). It is considered best practice to exclude any hospital 
patients as controls with other diseases that may be related to the exposure being 
investigated (Wacholder and Silverman, 1990). For example, a case-control study at a 
veterinary teaching hospital evaluated the association between Bartonella spp and 
chronic rhinosinusitis (CRS) in cats. Cats were excluded if they had outcomes thought to 
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be associated with Bartonella infection such as lymphadenopathy or uveitis (Berryessa et 
al., 2008). The rationale for this is that such controls would likely have a higher 
prevalence of Bartonella spp than cats without CRS from the source population because 
the exposure (Bartonella spp infections) was a factor associated with admittance.  If 
correct, the use of such a “sick” control group would have biased the association towards 
the null hypothesis. 
The “sick” control group may consist of multiple outcomes or a single disease 
outcome. The use of a single disease control group should be avoided due to potential for 
future research suggesting an association between the exposure and control group 
disease, as well as the difficulty in providing satisfactory evidence that the exposure and 
control group disease are not associated. A control group consisting of multiple diseases 
is preferred (Wacholder et al., 1992b; Rothman and Greenland, 1998). As an example of 
a multi-disease control group, a case-control design was used to investigate if recent 
vaccination was a risk factor for immune-mediated thrombocytopenia (ITP) in dogs. The 
disease control group was restricted only in excluding dogs with immune-mediated 
illnesses thus the control group consisted of dogs with an assortment of diseases (Huang 
et al., 2012). 
 As mentioned previously, controls should be randomly sampled from the same 
source population that gave rise to the cases to ensure the exposure distribution of the 
controls is representative of the exposure distribution of the non-diseased in the source 
population (Miettinen, 1985b). However when a secondary base is used, as with the 
hospital based case-control study, the study base is not explicitly defined and the selected 
controls are considered a non-random subset of the base. They are considered nonrandom 
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as these subjects are admitted patients and not truly random subjects from the source 
population (Wacholder et al., 1992a). It is important to stress that the subset is 
representative only of the study base and not of the entirety of animals without the 
disease or outcome of interest (Rothman and Greenland, 1998). 
The “nature” of the cases 
When designing a case-control study, a decision must be made whether to include 
prevalent, incident, or both outcome types as the cases. Prevalent cases are patients that 
already have the outcome of interest at enrollment. The use of prevalent cases is most 
applicable to assessing disease burden within a population as opposed to disease etiology 
(Pearce, 2004). Prevalent cases are also most suited to examining nonfatal chronic 
conditions, degenerative diseases, or congenital malformations (Rothman and Greenland, 
1998). For example, prevalent cases were enrolled in case-control studies to examine 
chronic gingivostomatitis in cats (Farcas et al., 2014), bovine cysticercosis (Calvo-
Artavia et al., 2013), or Cryptosporidium infection in calves (Silverlas et al., 2010). The 
main concern with employing prevalent cases is the difficulty in disentangling whether 
the exposure represents a cause or survival determinant in the population. Where 
prevalence suggests a current disease status, incident cases are patients with a “newly” 
diagnosed disease or outcome of interest and are thus better suited for examining disease 
etiology in case-control studies (Pearce, 2012). When deciding to employ incident cases, 
it is important to clearly distinguish between whether only animals experiencing the first 
occurrence or those with subsequent occurrences of the same disease will be included 
(Dohoo et al., 2009). As with studies based on prevalent cases, incident cases may be 
identified and exposure history ascertained via hospital records or prospectively as 
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admitted to the hospital or clinic. Finally, incident and prevalent cases may be enrolled in 
a case-control study. The authors of a survey on human case-control studies considered 
this situation to be analogous to the use of prevalent cases only but further discussion will 
not be considered here (Knol et al., 2008). 
As the focus of this review is on examining disease etiology, the use of incident 
cases will be the primary consideration throughout the remainder of this review. 
The number of control groups 
While a case-control study is typically thought of a comparison between one case 
group and one control group, multiple control groups may be considered. Observing 
multiple control groups may strengthen effect estimates when the results are consistent or 
assist in controlling potential biases (Ibrahim and Spitzer, 1979). For example if the 
different control groups are included to account for different potential confounders 
(Wacholder et al., 1992b). The different control groups may reflect different study base 
types (primary versus secondary) or different disease categories (e.g. animals with 
respiratory diseases as one control and animals with gastrointestinal disorders as a second 
control group) selected from hospital records. A human case-control study, observed 
similar effect measures when comparing controls from a primary study base (based on 
random digit dialing) versus controls from a secondary study base (based on “healthy” 
partners) (Pomp et al., 2010). Other human studies have suggested hospital controls may 
not be representative of the source population as the controls may be more similar to the 
cases than would otherwise be expected leading to differences in effect measure 
estimates. This situation was observed when patients with cervical cancer were enrolled 
as cases and a comparison was made between controls identified from the population (via 
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random digit dialing) and controls recruited from the hospital with gynecological 
disorders other than cancer (West et al., 1984). However, it is usually suggested to choose 
the control series most suitable to the association of interest ahead of time (Wacholder et 
al., 1992b; Moritz et al., 1997). 
Size of the control group 
Control group size or more specifically the ratio of controls to cases impacts the 
precision of the exposure-disease association. When there is an abundance of available 
cases and controls and the cost of data ascertainment is equal, it is suggested to use a ratio 
of one to one (Breslow and Day, 1980). In this scenario, the sample size should be 
calculated based on standard calculation methods beyond the scope of this review 
(Schlesselman and Stolley, 1982). If there is a cost difference between obtaining case and 
control patients, a ratio should be used. A ratio of three to four controls per case is 
generally considered to be the maximum in terms of precision, i.e. including more than 
four controls per case does not increase effect measure precision.  The statistical rationale 
is beyond the scope of this review but has been described elsewhere (Ury, 1975; Gail et 
al., 1976; Walter, 1977). 
Population type  
Based on the source population, the population may be considered one of two 
types: fixed cohort or a dynamic population. Case-control studies are often considered to 
be “nested” within a larger hypothetical cohort study or more generally within the source 
population from which the cases arose (Rothman and Greenland, 1998). When the cases 
and controls are selected from a specifically defined population where no additional 
individuals could conceivably be enrolled it is considered a fixed cohort. Fixed cohorts 
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(also known as closed populations) are not stable with regard to the exposure distribution 
and other group characteristics as members will die or leave the geographical area 
(Greenland et al., 1986; Rothman and Greenland, 1998). As an example, a case-control 
study was undertaken to examine risk factors for stillbirths in pigs. Farms in Brazil were 
recruited between a specific calendar time and all farrowing pigs were monitored for 
stillbirths (as the outcome) (Silva et al., 2015). This is a fairly common type of fixed 
cohort in veterinary and human research, namely a birth cohort. For an example other 
than a birth cohort, Lefebvre et al. (2009) defined fixed cohorts based on dogs that visited 
human health care facilities versus other animal assisted activities. 
Alternatively, a dynamic population (also known as an open population) may be 
considered where individuals can enter or leave the population during the study period. 
This state of flux will occur through immigration, emigration, birth, or death (Rothman 
and Greenland, 1998). The use of hospital based records to identify cases and controls 
would typically be considered from a dynamic population. Patient owners may enter or 
leave the surrounding area that feeds the hospital or decide they prefer a neighboring 
hospital for any number of reasons. These owners would no longer be considered as part 
of the source population. For example, to investigate risk factors for cranial cruciate 
rupture in dogs, medical records spanning 12 years from a small animal hospital were 
examined to identify cases and controls (Adams et al., 2011). This population served by 
the animal hospital would have to be considered dynamic. There are however exceptions 
and a fixed cohort may be described from a hospital based case-control design. For 
example, a hypothetical case-control study could be used to examine the association 
between number of days a patient spends in the hospital and methicillin resistant 
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Staphylococcus pseudintermedius (MRSP) infection during an outbreak within the 
hospital. Here the source population would be considered fixed or closed if the controls 
were selected from patients admitted to the hospital during the outbreak. The population 
type will ultimately play a role in additional considerations that effect how the odds ratio 
may be interpreted such as the timing of control selection. 
Timing of control selection 
There are three options for the timing of control selection: at the beginning of the 
study period, concurrently as cases are enrolled, and at the end of follow-up. 
Controls may be selected from the source population at the beginning of follow-
up. This type of sampling scheme is referred to most commonly as a case-cohort design 
(Prentice, 1986). This design choice has also been termed an inclusive design (Rodrigues 
and Kirkwood, 1990), case-base (Miettinen, 1982), or hybrid retrospective (Kupper et al., 
1975). This control sampling method identifies controls from a fixed cohort that were 
considered at risk before incident cases of disease were selected. That is a subcohort is 
randomly selected from the entire cohort and exposure history and other relevant 
characteristics are assessed (Prentice, 1986). The primary objective is again to sample 
controls such that their exposure distribution estimates the exposure distribution of the 
source population, which in this case is the fixed cohort. The primary advantage of this 
sampling strategy is it allows for the investigation of multiple disease outcomes using the 
same cohort of animals. For a review of the advantages and disadvantages of this 
sampling design see (Wacholder, 1991). As an example of this sampling approach, 
O'Connor et al. (2012) obtained eye swabs from all calves born on two different farms in 
a single year (fixed cohort) and followed the calves for the development of infectious 
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bovine keratoconjunctivitis (IBK). The authors of this study employed a population-
based cohort design to assess the association between IBK and different Moraxella spp. 
However if a randomly selected subcohort of calves that became cases (infected with 
IBK) were to be compared (i.e. isolation of Moraxella spp.) to calves that did not, this 
would have been considered a case-cohort design. 
A second control sampling strategy is to sample the controls concurrently as cases 
are enrolled (Miettinen, 1976; Greenland et al., 1986). In other words, the controls are 
selected from the source population at risk at the same calendar time a case is selected. 
For instance if computer records were used to find cases, controls could be selected 
among patients admitted or diagnosed on the same day as the case. With this type of 
sampling approach, controls may become cases but not vice versa. That is, a patient 
selected as a control may develop the disease during the study period but a patient with 
the disease is no longer at risk and thus cannot be considered as a control (Rodrigues and 
Kirkwood, 1990). This approach may be employed when the source population is either a 
fixed cohort or dynamic. When controls are selected in this manner from dynamic 
populations it is typically referred to as incidence density sampling (Miettinen, 1976). For 
example, a case-control study examining risk factors for bovine neonatal pancytopenia 
(BNP) used a fixed cohort and enrolled age- and farm-matched controls at the time a case 
was identified (Jones et al., 2013). 
The third sampling approach entails selecting controls from non-cases at the end 
of follow-up. That is, patients that remain disease free and are thus still considered at risk 
at the study end. This is the traditional way in which the case-control design is taught. 
This type of sampling is referred to as cumulative-incidence (Greenland and Thomas, 
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1982), traditional or exclusive design (Rodrigues and Kirkwood, 1990). It is with the 
teaching of this sampling strategy that the often mistaken “rare-disease” assumption is 
included (discussed below) (Cornfield, 1951; Rothman and Greenland, 1998). 
Discussion of how the sampling strategy and additional assumptions impact the 
effect measure interpretation is included below. 
Design Considerations for the Practical Management of Common Biases 
An important goal of all study designs, observational or experimental, is to have 
internal validity. That is, except for random error, the estimated effect measure based on 
the study sample is accurate for the source population. Biases of some form or another 
will affect the internal validity of all study designs. There are numerous biases in 
observational research (Sackett, 1979). It is thus important to control for potential biases 
in the design of a case-control study in order to minimize a possibly distorted effect 
measure. A common way to classify biases is in three categories: selection, information, 
and confounding (Dohoo et al., 2009). As confounding is a common concern in case-
control studies it will be briefly introduced below however extensive discussions of 
selection and information biases are beyond the scope of this review but are described in 
numerous places (Schlesselman and Stolley, 1982; Wacholder, 1995; Rothman and 
Greenland, 1998; Hernan et al., 2004; Dohoo et al., 2009). 
One of the most important concepts in observational study design is the control of 
confounding. A confounding factor can distort the effect measure between the exposure 
and disease of interest when not controlled. Where randomization in a controlled trial 
attempts to set baseline factors to be equal between study groups, case-control studies 
(and other observational designs) do not enjoy such luxury. As a result, differences 
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related to disease risk may inherently exist between study groups. Put another way, the 
cases and controls identified from the source population in a case-control study may have 
underlying disease risk differences due to some additional factor (the confounder) that 
when compared will result in a distorted or confounded association (Greenland and 
Robins, 1986). Although not sufficient, there are three criteria that suggest a factor is a 
confounder as described by Rothman and Greenland (1998): the confounding factor is 
either itself a cause or proxy for a different cause of the disease, is associated with the 
exposure in the source population such that it “causes” the exposure [for a case-control 
study this means an association in the control group (Miettinen and Cook, 1981)], and it 
may not be intermediary between exposure and disease. For additional information on 
how to deal with the situation in which the confounder is an intermediate step between 
exposure and disease see (Robins and Greenland, 1992). 
There are two main methods in which to address the issue of confounding in the 
case-control design: restriction, matching, and analytical methods. 
Restriction 
One of the simplest and most effective design choices to control for confounding 
is restriction (Greenland and Morgenstern, 2001). Restriction or restricted sampling refers 
to the exclusion of study subjects based on one level of a potential dichotomous or 
categorical confounding factor. If the confounder is measured on a continuous scale, 
suitable ranges can be determined as exclusionary criteria. As confounding is the result of 
an uneven distribution of an exposure-disease associated variable across study groups 
(here cases and controls), excluding subjects possessing one level or narrow range of that 
variable will effectively control the impact of that confounding variable. Proper restricted 
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sampling will thus result in all study subjects having the same level of the confounding 
variable. When restriction is based on dichotomous or categorical variables, Dohoo et al. 
(2009) suggest including subjects from the low-risk group (i.e. individuals with the level 
of the variable believed to be lower risk). Restriction may be based on any measureable 
confounding variable such as age, weight, breed, dam parity, or even hospital attended in 
a multicenter case-control study. For example, Wakeling et al. (2009) restricted their 
investigation of risk factors for hyperthyroidism to cats in the United Kingdom that were 
eight years of age and older. 
Thoughtful consideration should be given before implementing restriction 
however. Restricted sampling will result in a decrease in the number of available 
potential study subjects. This decrease will become more exaggerated if more than one 
exclusionary criterion is implemented. Additionally, as all subjects will have the same 
value for the restricted factor, the effect of factor cannot be examined in the analysis. 
Furthermore, restriction of potential subjects may result in reduced generalizability of 
study results (external validity). If a case-control study were restricted to overweight 
Himalayan cats for example, careful discussion would be required in order to generalize 
any observed exposure-disease association to cats at large. 
Matching 
Matching is the pairing of individual controls to cases based on one or more 
measurable variables (e.g. breed, weight, age). Matching in a case-control study is the 
selection of the control series such that the distribution of a potential confounder is 
identical (or approximately identical) to that of the cases (Schlesselman and Stolley, 
1982; Rothman and Greenland, 1998). Matching may be based on one or more potential 
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confounding factors. A hospital based case-control study may take advantage of a large 
database of potential controls that could be matched to cases based on a number of 
factors (e.g. age, weight, breed, reproductive status). Multiple matched controls may be 
selected for each case with careful considerations (Miettinen, 1968). This type of 
matching is also referred to as individual matching. 
Frequency or category matching on the other hand consists of selecting the 
controls such the distribution of the matching factor is equal to that of the cases (Karon 
and Kupper, 1982). For example, if 60% of the case series consisted of Miniature 
Pinschers and 40% German Shepard, controls would be selected to ensure approximately 
60% were Miniature Pinscher and 40% German Shepard. Frequency matching is 
seemingly less common in the veterinary sciences but for case-control studies it has been 
argued to be more efficient than pair matching (Karon and Kupper, 1982). 
Matching does not prevent confounding per se, but rather increases the efficiency 
of confounding control by ensuring approximately equal distribution of cases and 
controls across a confounding factor strata (Breslow and Day, 1980; Kupper et al., 1981; 
Rothman and Greenland, 1998). As a result of the balanced (or equal distribution) of 
cases and controls across a matched factor, the effect measure of interest may have 
decreased variance (i.e. increased efficiency) (Kupper et al., 1981). There are however 
exceptions to this and matching may result in decreased efficiency when there is no 
confounding of the association of interest (Thomas and Greenland, 1983). Practical 
recommendations based on statistical efficiency have been previously outlined by 
Thomas and Greenland (1983). 
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Importantly, if matching is implemented for the enrollment of controls, stratified 
or matched analysis must be conducted in order to ensure validity of the reported effect 
measure (Schlesselman and Stolley, 1982). For example, Stavisky et al. (2011) 
investigated risk factor for diarrhea in dogs where controls were matched to cases for 
both the timing of case presentation and clinic visited, and the analysis was conducted in 
a matched fashion (conditional logistic regression). 
Analytical methods 
The two most common analytical methods employed to control for confounding 
in case-control studies are stratification and regression models. These two approaches 
will be briefly described in practical terms; more thorough discussions may be found 
elsewhere (Breslow and Day, 1980; Rothman and Greenland, 1998; Dohoo et al., 2009; 
Kleinbaum and Klein, 2010). 
Stratified analysis is the simplest method in which to control for confounding in 
the association between exposure and disease. This analytical technique relies on 
separating or rather stratifying the data based on the confounding variables that were 
measured or assessed from the study subjects. When confounding variables are 
homogenous within each stratum, the impact of those variables in distorting the 
association is removed. To implement a stratified analysis, the following steps may be 
considered: 1) calculate and examine the odds ratios of each defined stratum, 2) conduct 
a statistical test for homogeneity (i.e. are the stratum-specific odds ratios equal at 
significance level α?), 3a) if the null hypothesis of homogeneity is rejected report each 
stratum-specific odds ratio separately, 3b) if homogeneity is considered reasonable, a 
single pooled estimate may be calculated. Typically, when the variables under study are 
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dichotomous, the pooled estimate will be a Mantel-Haenszel estimator or Mantel-
Haenszel odds ratio, which is a weighted average that can be calculated by hand or with 
user-friendly open source software such OpenEpi (Open Source Epidemiologic Statistics 
for Public Health) (Mantel and Haenszel, 1959; Sullivan et al., 2009). Alternatively, a 
logistic regression model may be used with conditional maximum likelihood estimators 
which are not based on stratum-specific weights and require more involved calculations 
(Breslow and Day, 1980; Kleinbaum and Klein, 2010). The main advantage of employing 
a logistic model for analyzing matched data from a case-control study is the ability to 
control for other measured variables that may have an effect on the exposure-disease 
association (Kleinbaum and Klein, 2010). 
It should be noted that statistical tests of homogeneity are of lower power, and 
some authors recommend the assumption homogeneity should be based on the judgment 
and biological knowledge of the researcher (Greenland, 1983; Rothman and Greenland, 
1998). 
When multiple confounders are measured and the dataset is stratified across those 
measured confounders, a “sparse-data” issue may arise. This problem occurs when some 
strata have fewer individuals as a result of the multiple stratifications and comparing 
exposed and unexposed is not valid or even possible (Greenland et al., 2000). Conditional 
logistic regression models can be used to minimize this issue but should be carefully 
considered as this method is not guaranteed to be effective and other methods (well 
beyond the scope of this review) might be considered (Greenland et al., 2000). As with a 
stratified analysis, the decision to utilize a regression model in the analysis requires the 
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measuring of all potentially relevant covariates a priori to beginning the study. 
Additional information may be found elsewhere as suggested above. 
Interpretation of the Odds Ratio  
The follow section describes the odds ratio (or cross-product ratio) in two ways: 
proper interpretation compared to risk or rate ratios and what the cross-product ratio 
estimates based on the above control sampling methods. 
Describing the odds ratio 
The odds ratio is the most common effect measure derived from case-control 
studies. Where probability is the proportion of event (or disease outcome) occurrence if 
observed many times (ranging from zero to one), odds are the ratio of the probability of 
event occurrence to the probability of no event (ranging from zero to infinity) (Grimes 
and Schulz, 2008). An odds ratio is thus the ratio of the odds calculated for two different 
groups. For a case-control study, the odds ratio is typically the odds of exposure in the 
cases divided by the odds of exposure in the controls, termed an exposure odds ratio. As 
the defining feature of the case-control design is the sampling on an outcome or disease 
status, only the exposure odds ratio can be directly calculated. This ratio is 
mathematically equivalent to the ratio of the odds of disease in the exposed to the odds of 
disease in the non-exposed which is more valuable in making estimates about disease 
“risk” (Sackett et al., 1996). However, the odds (or odds ratio) may not be interpreted as a 
risk and is often regarded as non-intuitive owing to the difficulty in the proper 
interpretation. As an effect measure, odds ratios may be calculated for most any study 
design. 
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Importantly, odds are different than risk or rate. The risk refers to the probability 
(expressed as a proportion or percentage) that a person develops the outcome over the 
time period under study. The rate on other hand refers to the rate at which at risk study 
subjects develop the outcome. The rate is calculated as the number of study subjects at 
risk over the combined person years of all participants (Rothman and Greenland, 1998; 
Vandenbroucke and Pearce, 2012b). The risk (or rate) ratio from an appropriately 
designed study is thus the risk proportion in one group (e.g. exposed individuals from a 
cohort study) divided by the risk proportion in a second group (e.g. unexposed 
individuals). For clinicians, this relative measure is much more intuitive and easier to 
understand as it describes the likelihood for developing a disease outcome in terms of a 
probability. 
The distinction between relative effect measures, specifically the odds and risk 
ratios, may be often confused or misinterpreted (O'Connor, 2013). Altman et al. (1998) 
reported on an example where the odds ratio calculation was described as “88 times more 
likely”. While the calculation was indeed correct, the risk ratio was only 7 and thus 
interpreting 88 as a probability is wholly misinforming. Holcomb et al. (2001) searched 
for studies reporting odds ratios from two human medicine journals over the course of a 
single year and observed the odds ratio erroneously interpreted as a risk ratio in a quarter 
of those studies. Importantly, interpreting the odds ratio as a risk ratio will always 
overestimate (i.e. further from the null value of one) the true association (Davies et al., 
1998). Interpreting the odds ratio as a risk ratio will rarely have an impact qualitatively 
(i.e. direction remains the same but the magnitude differs) (Davies et al., 1998). However 
under certain modeled conditions the odds and risk ratio may indeed be in opposite 
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directions of the null (Brumback and Berg, 2008). As suggested by O'Connor (2013), 
when reporting the odds ratio, it is important to avoid the terms risk or probability. 
There are however compelling reasons for which the non-intuitive odds ratio is a 
useful effect measure including; examining the association between two dichotomous 
variables (as in a 2x2 table), using logistic regression modeling techniques to control 
extraneous variables produces odds ratios, and the odds ratio has appealing statistical 
properties for use in pairwise- and network meta-analyses. 
Cross-product ratio estimation 
As mentioned above, the odds ratio is rather difficult to interpret properly. The 
odds ratio is itself a characteristic of the study population, thus suggestions that the odds 
ratio will estimate a risk or rate ratio are not entirely accurate as described by (O'Connor, 
2014). However, the calculation of the odds ratio, may estimate a risk or rate ratio 
depending on study design considerations. The final section of this review will thus 
consider those design options that were introduced earlier and how they impact the 
interpretation of the odds ratios calculation.  
The calculation of the odds ratio from a standard 2x2 table is commonly referred 
to as a cross-product ratio. It is called a cross-product ratio as the odds of the outcome in 
the exposed divided by the odds of the outcome in the non-exposed is mathematically 
equivalent to multiplying and dividing the corners from a 2x2 table. The odds ratio may 
also be derived from the exponent of the covariate of interest from a regression model 
[see Kleinbaum and Klein (2010) for more detailed discussion]. For simplicity, the 
remainder of this section will describe how the cross-product ratio may estimate other 
relative effect measures but these considerations hold for model based calculations as 
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well. The information of the following sections has been wonderfully illustrated (Figure 
1) by Knol et al. (2008). 
Incident cases from a fixed cohort 
When incident cases are chosen and the source population is considered fixed 
(e.g. an infectious disease outbreak in a hospital over the course of six months), the three 
main choices for the timing of control sampling and additional assumptions will impact 
the interpretation of the cross-product ratio. If controls are sampled from the beginning of 
follow-up (i.e. a case-cohort design), the cross-product ratio will estimate a risk ratio if 
study subject losses to follow-up are not related to exposure status (Kupper et al., 1975; 
Greenland et al., 1986; Vandenbroucke and Pearce, 2012a). As a hypothetical example, 
in a hospital based case-control study of a MRSP outbreak, cases could be selected from 
dogs that tested positive for MRSP during the defined outbreak period. The controls 
could theoretically be selected at random from all dogs that entered or were already in the 
hospital at the start of the outbreak. The cross-product ratio calculated from such a study 
would on average be a good estimate of the risk ratio, a far more easily interpreted effect 
measure. 
Alternatively, if controls are sampled concurrently (i.e. control subjects selected 
from the hospital records on or approximately the same day as each case is enrolled) and 
the analysis is matched on time, the cross-product ratio will estimate a rate ratio 
(Greenland and Thomas, 1982; Langholz and Thomas, 1990; Vandenbroucke and Pearce, 
2012a). The cross-product ratio will estimate a rate ratio as opposed to a risk ratio 
because the time matched control subjects (patients at risk for the outcome) represent the 
combined person years which are used to calculate in a rate ratio in a cohort study for 
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example (Rodrigues and Kirkwood, 1990). Jones et al. (2013) employed this design 
strategy to examine risk factors for bovine neonatal pancytopenia (BNP). As their 
analysis was matched on time, the resulting odds ratio from the logistic regression 
analysis conducted by the authors would estimate the rate of BNP incidence in the calves 
under study. 
Finally, when controls are selected from a fixed cohort at the end of the study 
period, and the disease being investigated is considered rare in the population, the cross-
product ratio will estimate a risk ratio (Miettinen, 1976; Vandenbroucke and Pearce, 
2012a). This is the traditional way in which case-control studies have been taught and 
specifically with the notion of the “rare disease assumption” introduced by Cornfield 
(1951). Indeed, a recent survey of case-control studies in the veterinary science observed 
that of seven studies employing incident cases from a fixed cohort, four sampled controls 
from subject at the end of follow-up. 
Incident cases from a dynamic population 
When a case-control study is designed such that incident cases and controls are 
selected from a dynamic population (i.e. a population continually in flux such as patients 
for a large referral hospital), the main consideration in interpretation of the cross-product 
ratio is the matching of controls to cases on time. When controls are matched to cases on 
time, the cross-product ratio will estimate a rate ratio without additional assumptions 
(Greenland and Thomas, 1982). If controls are not matched to cases on time, the cross-
product ratio will still estimate a rate ratio if the population can be considered stable. That 
is, the distributions of the variables under study, in particular the exposure, are not likely 
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to change meaningfully over the course of the study (Greenland et al., 1986; Knol et al., 
2008). 
Conclusions 
This review summarized the relevant design and interpretation aspects of the 
hospital-based case-control study. Specifically, the population source, the nature of the 
cases, selection and timing of valid control enrollment, considerations of matching and 
restriction, proper interpretation of the odds ratio, and design strategies to enable a more 
interpretable effect measure were described. Importantly, when the case-control study is 
properly described and reported in the literature, more value from the study can be 
obtained. For example, often times systematic reviews will exclude case-control studies 
as they are believed to be of less inferential value. If an excluded case-control study 
estimated a risk ratio comparable to what would have been observed had a cohort study 
been conducted, excluding that case-control study would result in the loss of potential 
valuable information in understanding a disease etiology.  
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Glossary 
Accuracy: How close a measurement mirrors the true value. 
Efficiency: The value of information from a study considering both time and money cost 
considerations or statistical efficiency related to estimate precision. 
Precision: The lack of random error as related to reproducibility. 
Validity: Inference derived from a study is accurate with regards to the source population 
from which study subjects were drawn (internal validity) or to individuals not included in 
the source population (external validity). Also relates to a lack of bias.  
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CHAPTER 3. THE CASE-CONTROL DESIGN IN VETERINARY SCIENCES: A 
SURVEY 
A paper submitted to Preventive Veterinary Medicine 
Jonah N. Cullen, Jan M. Sargeant, Kelly M. Makielski, Annette M. O’Connor 
Abstract  
Background: The case-control study design is deceptively simple. A number of design 
considerations affect the effect measure estimated by the design. An investigation of case-control 
studies in the human literature suggested a number of these considerations are not described in 
reports of case-control studies. 
Hypothesis/Objectives: The hypothesis was that the majority of veterinary studies labeled 
case-control would be incident density designs and many would not interpret the effect measure 
obtained from those studies as the rate ratio rather than the odds ratio. 
Methods: Reference databases were searched for author designated case-control studies. 
A survey of 100 of these studies was conducted to examine the different design options 
described and estimated effect measures. 
Results: Of the 100 case-control studies, 83 assessed a disease etiology or causal 
association and of those only 54 (65.1%) sampled the study population based on an outcome and 
would thus be considered case-control designs. Twelve studies were incidence density designs 
but none used this terminology. Of the studies that reported an odds ratio as the effect measure, 
none reported on additional considerations that would have enabled a more interpretable result. 
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Conclusions: The survey indicated many case-control labeled studies were not actual 
case-control designs and among case-control studies key design aspects were not often 
described. The absence of information about study design elements and underlying assumptions 
in case-control studies limits the ability to establish the effect measured by the study and their 
evidentiary value might be underestimated. 
Introduction 
Background and rationale  
In 2008, a survey was conducted of 150 case-control studies in human medicine that 
assessed the study design elements, underlying assumptions, and interpretation of the results 
(Knol et al., 2008). The survey findings suggested that many authors did not interpret the 
calculation of the odds ratio (OR) as a rate or risk rate when possible. For example, the stable 
population assumption, required for the OR calculation to estimate a rate ratio, was not stated by 
any of the authors in their sample. Knol et al. (2008) results may have been associated with 
recent case-control studies appropriately reporting necessary assumptions, additional surveys of 
case-control studies in specific topic areas, and rethinking of the use of case-control designs in 
human health (Fullerton et al., 2012; Goldberg et al., 2013; Touvier et al., 2013; Adam et al., 
2015). Although debate about the principles, conduct, reporting, and interpretation is not new 
(Greenland and Thomas, 1982; Wacholder et al., 1992a; Wacholder et al., 1992c; von Elm et al., 
2007; O'Connor, 2013).  
The case-control study is one of the “big three” observational study designs: cohort, case-
control, and cross-sectional designs (von Elm et al., 2007).  These designs are frequently used to 
assess exposure and outcome associations, i.e. etiology. Often the outcome is a disease, although 
not always. For simplicity, disease etiology will be used throughout this manuscript instead of 
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exposure-outcome association when possible. The case-control design is described as one of the 
most efficient choices for a research question regarding disease etiology. This is due to the 
relative inexpensive nature of the design in both assessment of exposure (as a result of assessing 
only a sample of the population) and the lack of required follow-up time (Rothman and 
Greenland, 1998). These benefits are even more pronounced when the outcome of interest is 
rare. For these reasons, the case-control design is often conducted in the early stages of 
investigating a disease etiology. However, while comparatively inexpensive and efficient, the 
case-control design can be complex to conduct, requiring close attention to detail, suitable case 
and control selection, and interpretation of the effect measure obtained from case control studies. 
Case-control designs are characterized by the selection approach into the study based on 
the outcome rather than exposure. This selection approach is the defining feature of the case-
control study design. Although often the outcome of interest in a case-control study is the disease 
status of the cases, hence the name, this is not a requirement of the case-control design. For 
example, what would be considered an exposure in a cohort study may be used as an outcome in 
a case-control design. That is, if investigators were interested in examining the association 
between a disease (exposure) and the development of a secondary disease (outcome), a case-
control study could be designed such that cases are enrolled based on the secondary disease. 
Subjects included in the study with the outcome of interest are considered the case population 
(cases) and subjects from the same source population without the defined outcome are 
considered the control population (controls). 
There are four main considerations when designing, reporting, and properly interpreting a 
case control study: 1) nature of the enrolled cases (incident or prevalent) (Pearce, 2012), 2) type 
of source population (fixed cohort or dynamic) (Miettinen, 1985b; Rothman and Greenland, 
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1998), 3) the source and timing of control selection (Miettinen, 1985a; Wacholder et al., 1992b) 
and 4) necessary assumptions and analyses considerations (Greenland and Thomas, 1982; 
Schlesselman and Stolley, 1982). The choice of incident or prevalent case enrollment will be 
referred to as “case type” throughout this manuscript. The interactions of these four design 
features affect the inference that can be obtained from a case-control study, and importantly the 
evidentiary value of the results. Figure 1, gratefully reproduced from Knol et al. (2008), depicts a 
flow diagram of these design features and will be referenced throughout this manuscript. 
Objectives 
Given the common use of the case-control design in veterinary clinical science and the 
findings of Knol et al. (2008), our objective was to determine if similar reporting issues occur in 
veterinary sciences with the case-control design. Our approach to addressing this objective was 
to replicate the Knol et al. (2008) study in veterinary science with small modifications. We 
examined case-control studies for the source population type, nature of the selected outcome, 
timing of control selection, and reporting of assumptions. Our working hypothesis was that the 
majority of veterinary studies using the case-control label would be incident density studies and 
that many authors would not report the effect measure obtained from those studies as the rate 
ratio but rather than the odds ratio. 
Methods 
Study design 
The study was envisaged as a descriptive hypothesis-generating study. To address the 
objective, a survey was conducted to characterize a sample of studies, designated by the original 
authors as case-control studies, by their “true” design based on the described characteristics. 
Both Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and 
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Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines 
were considered in preparing this manuscript (von Elm et al., 2007; Moher et al., 2009). 
Information sources and electronic search 
The Center for Biosciences and Agriculture International (CABI) and MEDLINE® 
databases were searched to identify potentially relevant manuscripts published in English since 
2006 via the Web of Science interface through Iowa State University. The search was designed 
to capture manuscripts that were described by the authors as "case control" in either the title or 
abstract using the Web of Science “Topic” and “Title” field tags (Table 1). The “Title” field tag 
specifically searches within the title field for both CABI and MEDLINE. Relevant to our search, 
the “Topic” field tag for CABI searches within the title (including foreign titles), abstract, 
descriptors (including organism and “up-posted” descriptors), identifiers, and CABICODES. For 
MEDLINE, the relevant fields in which the “Topic” field tag searches are the title, abstract, 
Medical Subject Heading (MeSH) terms, and keyword list. Database searches were conducted in 
June of 2015. The species chosen were based on convenience, relevance to the veterinary 
science, and anticipated size of the published literature available. The search used two concepts 
“case control” and species. The species chosen were cats, dogs, pigs, cows, and horses. The time 
limit (post 2006) was imposed because it was considered more relevant to study recently 
published studies and more of such studies would be available electronically.  
Study selection – refining the results of the electronic search 
Citations retrieved by the electronic searches were downloaded and duplicate manuscripts 
were identified and removed via EndNote X7.5a. The remaining citations were imported into the 
online systematic review software DistillerSRb, which was used to manage all manuscripts and 
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associated data. After importing into DistillerSR, duplicate studies not identified in EndNote 
were removed using the DistillerSR “Duplicate Detection” tool.  
A single reviewer (JC) conducted the initial screening to identify all eligible manuscripts 
that were author designated as case-control in the title or abstract. Manuscripts not specifically 
described as some form of case-control were excluded. To be eligible, the abstract or title needed 
to include the terms “case” and “control” adjacently; descriptions of cases and controls only were 
not considered. Of the manuscripts eligible following the initial screening, 100 manuscripts were 
then randomly selected (using the DistillerSR random sorting function) for further evaluation and 
the full texts obtained. After obtaining the full text, manuscripts were removed for any of the 
following reasons: upon closer examination “case control” was not described in the title or 
abstract, the manuscript was a preliminary report, did not assess an animal health outcome, or 
was not available in English.  Manuscripts were replaced (randomly) as needed, in order to end 
up with a total of 100.  
Data collection process – quality control approaches for data extraction 
The data extraction form was pilot tested by three reviewers to ensure completeness of 
assessment and agreement. Example studies were extracted by all reviewers and results 
compared. The form was modified until all reviewers agreed.  
Two reviewers reviewed all studies, and conflicts were resolved by discussion. If two 
reviewers could not come to a consensus for any item of a manuscript, a third reviewer was 
included for adjudication. As part of the pilot test, the following guidelines were established to 
assess specific design features. If the two reviewers decided the presumed purpose of the study 
was a diagnostic test accuracy (DTA) study rather than assessment of an exposure-disease 
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relationship, no design elements were examined. Only if the study described using newly 
diagnosed patients were cases considered incident and we made no assumptions about the "lag 
time" between disease onset and case presentation. As an example, dogs might have Cushing’s 
disease (hyperadrenocorticism) for extended periods (perhaps months) prior to presentation at 
the veterinary clinic; however, we considered these incident cases when presented for the first 
time. Cases were considered prevalent when the authors stated patients were previously 
diagnosed or were described as having chronic disease symptoms. Note for hospital-based 
studies, authors rarely specifically indicated that cases were the first presentation, but often did 
indicate that cases had been previously seen. Diseases known to be recurrent or chronic in 
livestock were considered prevalent unless it was specifically stated as a newly diagnosed herd 
or animal. Congenital diseases were considered prevalent (Mason et al., 2005). For studies 
involving cats or dogs, an author (KM) was consulted if this case type was ultimately unclear. In 
deciding between population type (fixed cohort and dynamic), if no other patients could 
conceivably enter the source population it was considered a fixed cohort. Within dynamic 
populations, we made no assumptions regarding the validity of the timing of case to control 
selection.  
Data items – data extracted from manuscripts 
For the 100 manuscripts we extracted the species [later grouped by animal type: small 
animal (cat, dog) and large animal (cow, pig, horse)], year of publication, journal, and year(s) 
from which the study population was drawn. We then assessed the presumed purpose of the 
study based on the author description. Options included an etiology assessment, DTA, or 
unclear. The presumed purpose was considered to be a DTA based upon descriptions of novel 
diagnostic techniques or clinical scoring systems, reports of sensitivity and specificity, ROC 
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curves or likelihood ratios, or if the authors specifically stated the purpose was a test evaluation. 
Etiology assessment was considered to be the purpose if the authors appeared to be making 
inference about causation. The purpose was considered unclear if was not possible to 
differentiate between etiology assessment or DTA.  
For studies that were considered to have an etiology purpose, the next step was to extract 
information that would allow determination of the design based on the Knol et al (2008) 
schematic (Figure 1). This design information included sampling from the source population 
based on the outcome (yes, no, not discernable), unit of observation (individual, group, mixed) 
and the case type (incident, prevalent, mixed). For studies that did not state, or were unclear, as 
to whether sampling was on an outcome, inclusion of a longitudinal or temporal component was 
assessed. If the authors examined the exposure-disease association at a single point in time, it 
was considered a cross-sectional design and if one of these variables preceded the other, it was 
considered a cohort design. These studies were not investigated further as they were not 
considered to be case-control designs. Additionally, studies with unclear case type were not 
examined further as determining subsequent design considerations would be of little value. 
We also extracted the author specific name for the design (e.g. case-control design, 
retrospective case-control). Author specific design titles were summarized in order to produce a 
reasonable number of design descriptions. For example, a design title of “prospective, 
multicenter, unmatched case-control study” was summarized as “prospective unmatched case-
control”. Similarly, a “multi-country matched case-control study” was summarized as “matched 
case-control study”. 
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Finally for studies that did sample from the source population based on a clearly 
described case type [i.e. case-control studies with incident, prevalent, or both (mixed) case 
types], we extracted the following information to determine the effect measure that could be 
estimated: the presumed nature of the source population type (fixed cohort or dynamic source), 
the timing of control selection (beginning, end, or concurrently), the author stated underlying 
assumptions (censoring of study subjects not related to exposure, rare disease in the source 
population, matched analysis, stable exposure distribution), and the level of analysis (individual 
or group). Often authors did not report these factors but an interpretation based on the author’s 
description of the study was made. The author reported effect measures (e.g. odds ratio, rate 
ratio, risk ratio, regression coefficients) were also recorded for each study. If the disease state (or 
outcome) was not dichotomous, the reported effect measure was considered not applicable. For 
examining whether the OR calculation may estimate a rate or risk ratio, only studies 
investigating incident diseases from either a fixed cohort or dynamic population that provided 
OR (i.e. studies reporting prevalence OR or regression coefficients without transformation to an 
OR were excluded) were considered for the reporting of necessary assumptions. This was 
determined in conjunction with Figure 1, reproduced from Knol et al. (2008). 
Bias 
We did not expect any major sources of bias in our survey. We did not restrict our search 
by journal or species and randomly selected our sample population of studies from the source. To 
reduce information bias in data extraction, we used pretested forms and duplicate data extraction.  
Study size 
The rationale for the sample size was pragmatic as no prior information was available on 
which to base a sample size calculation. A sample size of 100 was chosen by one author (AOC) 
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because previously conducted studies of similar exploratory style used this size and it seems 
sufficiently large to provide a good “picture” of the topic (Sargeant et al., 2009; Sargeant et al., 
2010; Sargeant et al., 2011). Further, as we did not test any hypotheses, we did not need to 
evaluate power of the study to test a hypothesis. 
Quantitative variables 
We recorded no quantitative variables. 
Statistical methods and approach to summarization of results 
No statistical hypotheses were tested, and basic descriptive statistics were calculated to 
describe the frequency of design characteristics. Although statistical tests were not conducted to 
address the working hypotheses, descriptive statistics were used subjectively to report the 
frequencies of different sampling strategies (e.g. exclusive sampling versus incidence density 
sampling) and the assumptions stated for the effect measure estimation of the OR calculation. 
Results 
Study population 
The search resulted in 744 citations from CABI and 2,153 from MEDLINE. Following 
removal of duplicate manuscripts, 2,289 citations remained. Five hundred and fifty three were 
identified as some form of case-control study in the title or abstract by the authors. One hundred 
manuscripts were randomly selected, 12 of which were excluded and randomly replaced due to 
not being described as case-control upon examination of the full text (n=2), considered to be a 
preliminary report (n=2), not an animal health outcome (n=1), or were not available in English 
(n=7). 
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Descriptive data for general characteristics of studies 
The 100 self-described case control manuscripts were from 45 different journals with the 
Journal of the American Veterinary Medical Association most represented (n=16), followed by 
the Journal of Veterinary Internal Medicine (n=11), PLoS One (n=9), Equine Vet Journal (n=7), 
Preventive Veterinary Medicine (n=6) and Journal of Small Animal Practice (n=5) (Table 2). 
The most frequent year of publication was 2011. Of the 100 manuscripts, the presumed primary 
purpose was determined to be a DTA (n=14) or unclear (n=3). These 17 manuscripts were 
excluded from further characterization. The remaining 83 papers were considered to have an 
etiology purpose. 
Table 2 contains the design titles given by the authors of the 83 manuscripts. “Case-
control” (without additional descriptors) was the given design title for 30 of 54 (55.6%) studies 
that sampled on the outcome and 9 of 25 (36%) that did not. “Prospective” was used nearly 
equally between studies that did or did not sample on an outcome [compare 4 of 54 (7.4%) 
sampled on an outcome to 2 of 25 (8%) that did not]. The term “retrospective” was employed as 
a design title in 9 of 54 (16.7%) studies that sampled on the outcome and 12 of 25 (48%) that did 
not. 
Table 3 summarizes the general characteristics of the 83 manuscripts with the primary 
purpose of assessing a disease etiology, grouped by animal type [small animal (cat, dog) and 
large animal (cow, pig, horse)].  Of the 83 etiology studies, 54 (65.1%) sampled from the source 
population based on the outcome, suggesting a case-control design. Of the 54 studies, 37 (68.5%) 
were large animal and 17 (31.5%) were small animal. The remaining 29 studies did not sample 
from the source population based on the on the outcome [25 (30.1%)] and were either cohort 
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studies (longitudinal aspect included) or cross sectional studies (no longitudinal component), or 
the sampling method was not discernable [4 (4.8%)].  
Based on our selection criteria, all of these studies had been described by the authors as 
some form of case-control studies. These data indicate that 34.9% (95% CI: 24.7 – 45.2) of self-
described case-control studies with the purpose of assessing etiology are not correctly identified. 
Also, overall (combined with DTA and unclear purpose), 46% (95% CI: 35.3 – 56.7) of the self-
described case-control studies in our random sample were not actually that design.   
The sample set contained 52 large animal studies with a primary purpose of assessing a 
disease etiology. Fifteen of the 52 (28.9%) large animal studies did not sample on the outcome. 
For three of the 15 (28.9%), the sampling strategy was not discernable. Of the remaining 12 
(23.1%) studies that did not sample on the outcome, six employed a temporal component and six 
did not. These results suggest that six studies would more likely be a cohort study (with temporal 
component) and the other six as a cross-sectional (without temporal aspect). 
Thirty-one small animal studies were identified as having an etiology purpose. Fourteen 
of these 31 (45.1%) small animal studies did not sample from the source population based on the 
outcome (13) or it was not discernable (1). Eight of the 13 small animal studies that did not 
sample on outcome, 8 would be considered cohorts (with temporal component) and 5 would be 
considered cross-sectional studies (without temporal aspect).  
For the unit of observation, 62 of 83 etiology studies (74.7%) sampled at the individual 
level, 19 (22.9%) at the group level, and 2 (2.4%) enrolled both individuals and groups. No small 
animal studies employed a group level sampling whereas 19 or 52 (36.5%) large animal studies 
did.  
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Incident cases were most common in the etiology studies, with 45 of 83 (54.2%) studies. 
Prevalent cases were utilized in 23 of 83 (27.7%). The majority of prevalent case types were 
from large animal studies [19 of 23 (82.6%)], where as only 4 of 23 (17.4%) small animal studies 
employed prevalent cases. Of the 83, 3 (3.6%) studies used both incident and prevalent case 
types (referred to as “mixed”) and case type was unclear for 12 (14.5%). 
Approach to case selection in case-control designs 
The design features of the 54 studies (65.1%) that sampled on the outcome (thus 
considered case-control) are reported in Table 4. Twenty-nine studies were determined to be 
enrolling incident cases, and from studies utilizing incident cases, fixed cohorts with 7 of 29 
(24.1%) were less represented then dynamic populations with 22 of 29 (75.9%). Seventeen of the 
54 (31.5%) studies were considered to be enrolling prevalent cases. Both incident and prevalent 
cases were enrolled for 2 (3.7%) studies and the type of case was unclear for 6 (11.1%). 
Prevalent cases were utilized for large animal topics more often [15 of 37 (40.5%)] than small 
animal topics [2 of 17 (11.8%)]. The level of analysis was the group level for 12 of 37 (32.4%) 
large animal studies and no small animal based manuscripts. 
Approach to control selection in case-control designs 
The timing of control group selection is presented in Table 4. For studies that used 
incident cases [29 of 54 (53.7%)] within a fixed cohort [7 of 29 (24.1%)], controls were sampled 
concurrently [2 of 7 (28.6%)], at the end of follow-up [4 of 7 (57.1%)], or it was unclear [1 of 
7(14.3%)]. No studies in our sample selected controls at the beginning of follow-up; thus, none 
of sample studies would be considered a case-cohort. Twenty-two of 29 (75.9%) studies 
employed incident cases from a dynamic population. Of the 22, 10 attempted to match controls 
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to cases on time, 9 did not match on time, and for 3 it was unclear with regards to matching. 
None of the incident density studies described themselves as such.    
Effect measure reported by authors and inferred by reviewers 
Six of the 54 (11.1%) studies were excluded from additional examination, as it was not 
possible to determine how the effect measure may be interpreted without distinguishing between 
incident and prevalent cases. Table 5 contains the effect measures reported by the authors, 
stratified by animal grouping (small animal and large animal). The OR was reported as the sole 
effect measure in 30 of the 48 (62.5%) studies. Some authors reported the OR and regression 
coefficient (without transformation to a standard effect measure) [3 (6.3%)], the prevalence OR 
[2 (4.2%)], the regression coefficient [1 (2.1%)], or did not report an effect measure [9 (18.8%)]. 
Additionally, for 3 of the 48 (6.3%) studies, the reporting of the effect measure was considered 
“not applicable” as the outcome was not dichotomous. 
Table 6 presents the timing of control selection from fixed cohorts or dynamic 
populations in studies that reported the OR as the effect measure of interest (i.e. studies reporting 
solely the prevalence OR or regression coefficients without transformation to a standard effect 
measure were excluded). Only studies that solely employed incident case types were included 
(i.e. prevalence and incidence/prevalence based studies were excluded). Additionally the 
assumptions needed for the OR calculation to estimate a risk or rate ratio are displayed. 
Five studies (two small animal and three large animal) sampled cases and controls from 
within a fixed cohort (Table 6). Of the five studies, three sampled controls at the end of follow-
up, one concurrently, and for one the timing was unclear. No studies sampled controls from the 
beginning of follow-up, thus none would be considered case-cohort studies. When controls are 
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sampled at the end of follow-up, the rare disease assumption is required for the calculation of the 
OR to estimate a risk ratio. This assumption was not stated in any of the three studies. 
Concurrent sampling of controls requires the analysis to be matched on time in order for the OR 
calculation to estimate a rate ratio. The analysis was matched on time for the study that sampled 
controls concurrently from our sample. However the authors did not describe a rate ratio within 
the manuscript but instead used the term matched OR. 
Eighteen studies (seven small animal and eleven large animal) sampled cases and 
controls from a dynamic population (Table 6).  Of the 18 studies, eight matched and eight did not 
match the timing of control sampling to cases. The timing was unclear for two studies. For 
studies that matched the timing of control selection to case enrollment, no further assumptions 
are needed for the OR calculation to estimate a rate ratio (Greenland and Thomas, 1982). When 
control selection timing is not matched to cases, a stable population assumption is required 
(Greenland and Thomas, 1982). A population is considered or assumed to be stable when the 
study characteristics under study (e.g. exposure distribution) do not change significantly over the 
study period (Greenland et al., 1986). None of the eight studies that did not match timing of 
control sampling to cases suggested population stability. After extensive discussions, the authors 
of this manuscript determined all eight studies likely examined a disease etiology from a stable 
population. It should be noted, however that stability as a population characteristic is often 
debatable, because the assumption is a function of time, and experts may differ on the time frame 
for stability (Knol et al., 2008). For further discussion see Greenland and Thomas (1982) and 
Greenland et al. (1986). 
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Discussion 
Our survey of case-control studies in the veterinary literature suggests uncertainty as to 
what constitutes a case-control study and the assumptions needed for the OR to be more 
interpretable. Furthermore, it highlights incomplete descriptions of important methodological 
aspects in a number of our sampled manuscripts. 
Key results 
Our survey of 100 author designated case-control studies in the veterinary sciences 
resulted in greater than half of the studies that sampled from the source population based on the 
outcome (i.e. case-control design) and assessed a disease etiology or exposure-outcome 
association. Nearly a fifth (17) of examined manuscripts were DTA or had an unclear purpose. 
Of the studies that examined a disease etiology but did not sample on the outcome, almost half 
used sampling methods consistent with the cohort design and greater than half with cross-
sectional designs. This suggests that the approximately 30% of our sample that were not DTA 
but were labeled as case-control would actually better be described as cohort and cross-sectional 
designs. This is an issue in veterinary medicine that should be addressed. For example, a survey 
of observational designs for pre-harvest food safety also identified mislabeled study design 
descriptions (Sargeant et al., 2011). This finding has ramifications as it indicates authors, editors, 
or reviewers may be misinterpreting study design descriptions. As a result, if design labels are 
used as criteria for relevance or “quality” then mislabeled studies may be incorrectly excluded 
from consideration for research synthesis. This also has implications in terms of searches used to 
identify literature based on study design type. 
Of the manuscripts that that sampled on the outcome and were therefore consistent with a 
case-control design, over half utilized incident cases, a third prevalent cases, and the remaining 
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were either unclear or mixed case types. These results are in contrast to the previously observed 
results by Knol et al. (2008) for human case-control studies. The Knol et al. (2008) survey 
reported nearly all manuscripts enrolled incident case types (81%) and less than 10% prevalent 
case types. The difference, with regards to case type, between our veterinary survey and the 
human survey is less pronounced for case-control studies with small animals. Nearly two-thirds 
of the small animal case-control studies used incident cases and approximately 10% prevalent 
cases. However for large animal based case-control studies the ratio of incident to prevalent case 
types is nearly one-to-one. This is an important observation as it suggests that although 
veterinary researchers may be more likely (at least for small animal studies) to use incident cases 
with the case-control design, the frequency is less than that for human medicine. This implies the 
nuance in the choice of utilizing incident versus prevalent cases may not be entirely recognized. 
With such incident case based designs, if assumptions are properly reported, the estimation of the 
risk or rate ratio rather than the OR may be possible. This is helpful because the risk or rate ratio 
is more readily interpretable. Researchers understand the ratio of risks better than ratio of odds 
(Sackett et al., 1996; Davies et al., 1998; Grimes and Schulz, 2008; O'Connor, 2013). Authors 
are often warned not to treat the two effect measures as interchangeable because the OR is 
further from the null and therefore it over estimates the risk ratio in non-rare situations (Davies et 
al., 1998). However, that statement is only applicable to the small subset of case control studies 
that do estimate the OR. Knowledge of the actual case-control design would ensure correct 
interpretation.  
The relationship between fixed cohort and dynamic population usage among incident 
cases matched the observed relationship in human case-control studies (Knol et al., 2008). These 
results suggest that both human and veterinary researchers employ fixed cohort and dynamic 
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populations for case-control studies in similar proportions. This is an important observation as it 
implies veterinary researchers conducting case-controls are cognizant of the “fixed” nature of the 
source population from which the cases were drawn. This is especially true in the subset of our 
sample that recognized their case-control study was conducted within a cohort, as case-control 
studies may often be considered as “nested” within a hypothetical cohort (Rothman and 
Greenland, 1998). 
Where Knol et al. (2008) observed 90% of all case control studies reported an OR, only 
62.5% of our sample that sampled on the outcome and had a clear population type reported the 
OR as the effect measure. Prevalence ORs, regression coefficients, or no effect measure at all 
were reported. Unfortunately the necessary design and study population information required to 
determine if a study using incident cases actually estimated the risk ratio or rate ratio were not 
specifically stated in any of the sampled manuscripts. Among designs using incident cases and 
control sampling from fixed cohorts, only one study of five sampled concurrently and employed 
the essential assumption for the OR to estimate the rate ratio, namely the analysis be matched on 
time . However, the authors of this study did not report the calculation of the OR to be an 
estimate of the rate ratio. Among controls sampled from dynamic populations and of the 
manuscripts that matched controls to cases on time (thus no further assumptions needed), none 
reported the OR as an estimate of the rate ratio (two reported mortality rates). Additionally, the 
stable population assumption required when controls are sampled from dynamic populations that 
are not sampled on time was not specifically stated in any of the manuscripts employing this 
sampling strategy. As a consequence, a more interpretable effect measure of the causal 
association was missed in these studies. 
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The results of this survey indicate that issues exist in the designing, reporting, and 
implementing of the case-control study design in the veterinary science. Study subjects were not 
sampled on an outcome, the defining feature of the case-control design, in 35% of examined 
studies that assessed a disease etiology or exposure-outcome association. In many studies, the 
effect estimate was likely to have a more interpretable meaning than the odds ratio reported and 
incomplete reporting of the assumptions resulted in the loss of potentially important information 
from these studies. These findings have two implications: 1) filtering by author designated study 
design within a systematic review may result in the loss of relevant manuscripts if reported 
incorrectly, and 2) when conducting meta-analyses, it is unclear how to incorporate ORs if their 
calculation estimates a more interpretable risk or rate ratio based on design considerations. 
Overall, the results suggest an opportunity exists for epidemiologists to improve the teaching of 
the complexities of the case-control design to maximize potential etiologic inference from this 
misunderstood epidemiologic study design. 
Limitations 
Although we did not expect major sources of biases, our survey may contain some 
limitations or biases. We do not expect a large bias as a result of journal publication standards as 
we did not limit the search to specific journals. Our survey may be limited by our interpretation 
of the intended purpose of studies. For example, if the authors’ intended purpose was to 
investigate disease etiology but more prominently described aspects of a DTA, this study may 
have been misclassified as a DTA. We attempted to minimize this misclassification by looking 
for typical features (e.g. ROC curves, sensitivity and specificity analysis) and specific language 
(e.g. “to evaluate a novel diagnostic...”) of DTAs. 
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It may be argued that the chosen sample size of 100 is a limitation as our survey led to 
only 54 studies that were actually case-control designs. Moreover, of the 54, only 23 studies 
included incident cases from a fixed or dynamic population and reported an OR. As a result, the 
assumptions required for the OR calculation to estimate a risk or rate ratio were only assessed for 
less than a quarter of the original sample. This is in contrast to the results of Knol et al. (2008) 
where of the 150 case-control studies investigated, 135 reported an OR. Further, all 150 were 
examined for the reporting of effect measures and necessary assumptions. 
One of the possible biases is the amount of inference we were required to draw from 
studies, as authors did not state most assumptions, i.e. we may have made the wrong judgment. 
We attempted to minimize this incorrect assessment by using two independent reviewers per 
manuscripts and ensuring agreement across reviewers on the pilot set. Further, when 
disagreements arose with regards to outcome type (incident versus prevalent) or control selection 
and could not be resolved by discussion, we used "unclear" instead of guessing at the authors' 
intention. This may have caused us to under represent the number of studies that should have 
been included in the description of the effect measure and assumptions (Table 7). The lack of 
specific study design descriptions in a large number of our sample was not entirely unexpected. 
Our survey may also be biased by our search only including "case control". Veterinary 
studies employing a case-cohort design (hybrid case-control with controls sampled from the 
population at the beginning of follow-up) may have been missed if the authors used the term 
"case-cohort" and not "case control". Authors that recognize a case-cohort as a particular case-
control design may be conscientious of the proper reporting and necessary assumptions. As a 
result, the observation that none of our study sample included case-cohort studies is likely to be 
an underestimate of the veterinary science at large. However, it should be noted that Knol et al. 
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(2008) observed only 1 of 150 (0.67%) case-control studies that would be considered case-
cohorts. 
Generalizability 
Based on our survey of the veterinary literature and previous surveys in the human 
literature (Pocock et al., 2004; Tooth et al., 2005; Knol et al., 2008; Fullerton et al., 2012), we 
would suggest employing a different classification system. Historically, directionality and the 
use of the terms “retrospective” and “prospective” have been a source of confusion in defining 
study design (Vandenbroucke, 1991). With this confusion, case-control studies are often 
considered retrospective in nature and cohorts as prospective. In this survey, for example, nearly 
half of the studies labeled case-control that did not sample on an outcome (i.e. not “true” case-
control designs) used the term “retrospective” to describe the design. Thus in order to alleviate 
this confusion and better teach the case-control design, as well as observational design in 
general, a different classification system may be warranted. Indeed, one such classification 
scheme, originally proposed by Greenland and Morgenstern (1988) and Morgenstern and 
Thomas (1993), has been recently revived by Pearce (2012). This classification scheme 
specifically rejects the notion of directionality as a means of distinguishing between designs, and 
consists of two main considerations: 1) incident or prevalent case type, and 2) whether or not to 
sample on an outcome. These simplified design choices thus result in four basic designs: incident 
cases sampled on an outcome, incident cases not sampled on an outcome, prevalent cases 
sampled on an outcome, and prevalent cases not sampled on an outcome. Pearce (2012) argues 
that not only will this classification scheme emphasize that directionality is unimportant in 
distinguishing study design, but also highlight the importance of case type utilized, and the 
distinction between whether or not subjects are identified and enrolled based on the case type. 
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Our belief is that if authors were to employ this much simpler design scheme, there may be less 
uncertainty in adequately describing the overall study design for most observational study 
designs.  
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Footnotes 
a Endnote X7.5, Thomson Reuters, http://endnote.com 
b DistillerSR, Evidence Partners, https://distillercer.com   
 64 
Figures 
 
Figure 1. Schematic of case-control design options illustrating what the OR calculation will 
estimate. Reproduced with permission from Knol et al. (2008).  
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Tables 
Table 1. Literature review search terms to identify case-control studies in animals for the Centre 
for Biosciences and Agriculture International (CABI) and MEDLINE databases conducted on 
June 5th, 2015. 
Population AND Study design 
TS=(cat OR feline OR dog OR canine OR cow OR cattle OR bovine OR 
pig OR swine OR porcine OR feedlot OR “cow-calf” OR cow-calf OR 
herd) 
TS=(horse OR equine)* 
TS=(“case control”) OR TI=(“case 
control”)  
 
*The search including horses was conducted on June 26th, 2015.  
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Table 2. Study design titles for studies that did or did not sample on an outcome or sampling 
strategy was unclear. 
Sampled on an outcome (54) Not sampled on an outcome (25) Unclear sampling strategy (4) 
Case-control (30) 
Case-control association (1) 
Cross-sectional case-control (1) 
Genome wide case-control (2) 
Matched case-control (4) 
Nested case-control (2) 
Prospective case-control (1) 
Prospective nested case-control (1) 
Prospective unmatched case-control (2) 
 
Retrospective case-control (9) 
Unmatched case-control (1) 
Case-control (9) 
 
 
 
Matched case-control (1) 
 
Prospective case-control (2) 
 
 
Randomized blinded case-control (1) 
Retrospective case-control (12) 
Case-control (2) 
Case-control association (1) 
 
 
 
 
 
 
 
 
 
Unmatched case-control (1) 
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Table 3. Summary statistics of manuscripts author designated as case-control identified from 
database searches. [n (%) or mean] 
 Manuscripts (n=100) 
Journal (n= 100)  
Journal of the American Veterinary Medical Association 16 (16.0) 
Journal of Veterinary Internal Medicine 11 (11.0) 
PLoS One 9 (9.0) 
Equine Veterinary Journal 7 (7.0) 
Preventive Veterinary Medicine 6 (6.0) 
Journal Small Animal Practice 5 (5.0) 
Other* 46 (46.0) 
Presumed purpose (n= 100)  
Disease etiology 83 (83.0) 
Diagnostic test evaluation 14 (14.0) 
Unclear 3 (3.0) 
Species (n=83)  
Bovine 26 (26.0) 
Canine 21 (21.0) 
Equine** 16 (16.0) 
Feline 9 (9.0) 
Porcine 4 (4.0) 
Mixed 7 (7.0) 
* Other manuscripts across 39 other journals at less than five per journal. 
** One manuscript with donkeys as the study population.  
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Table 4. Summary statistics of 83 manuscripts with the presumed purpose to assess a disease 
etiology (i.e. not diagnostic test evaluation or unclear). [n (% of column subgroup)] 
 Small animal (n=31) Large animal (n=52) Total (n=83) 
Sampling on the outcome    
Yes 17 (54.8) 37 (71.2) 54 (65.1) 
No 13 (41.9) 12 (23.1) 25 (30.1) 
Not discernable 1 (3.2) 3 (5.8) 4 (4.8) 
Unit of observation    
Individual 31 (100) 31 (59.6) 62 (74.7) 
Group 0 19 (36.5) 19 (22.9) 
Mixed 0 2 (3.9) 2 (2.4) 
Case type    
Incidence 19 (61.3) 26 (50.0) 45 (54.2) 
Prevalence 4 (12.9) 19 (36.5) 23 (27.7) 
Mixed 3 (9.7) 0 3 (3.6) 
Not discernable 5 (16.1) 7 (13.5) 12 (14.5) 
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Table 5. Summary statistics of 54 manuscripts that were case control studies (sampled on the 
outcome) with the presumed purpose of assessing a disease etiology. [n (%)] 
 Small animal (n=17) Large animal (n=37) Total (n=54) 
Unit of observation    
Individual 17 (100) 18 (48.6) 35 (64.8) 
Group 0 18 (48.6) 18 (33.3) 
Mixed 0 1 (2.7) 1 (1.9) 
Control selection    
Incident cases 11 (64.7) 18 (48.6) 29 (53.7) 
Fixed cohort 2 (18.2) 5 (27.8) 7 (24.1) 
Beginning of 
follow-up 
0 0 0 
Concurrently 0 2 2 
End of follow-up 2 2 4 
Not discernable 0 1 1 
Dynamic population 9 (81.8) 13 (72.2) 22 (75.9) 
Attempt match on 
time 
4 6 10 
Not matched on 
time 
3 6 9 
Not discernable 
regarding time 
2 1 3 
Prevalent cases 2 (11.8) 15 (40.5) 17 (31.5) 
Incident & prevalent 
cases 
2 (11.8) 0 2 (3.7) 
Case type not 
discernable 
2 (11.8) 4 (10.8) 6 (11.1) 
Level of analysis    
Individual 15 (88.2) 17 (45.9) 32 (59.3) 
Group 0 12 (32.4) 12 (22.2) 
 70 
Table 5. continued 
Mixed* 0 3 (8.1) 2 (3.7) 
No analysis 0 1 (2.7) 1 (1.9 
Not applicable** 2 (11.8) 4 (10.8) 6 (11.1) 
* Mixed includes "Individual, Group" (2) and "Individual, Pool of individuals" (1) 
** Not applicable when case type could not be determined (i.e. unclear if incident or 
prevalent cases were included), or when additional design considerations, including the level of 
analysis, were not completed.   
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Table 6. Effect measure reported from 48 manuscripts that sampled on the outcome, were not 
presumed to be diagnostic test evaluations, and the population type (incidence/prevalence) was 
clear from the authors' description. [n (%)] 
 Small animal (n=15) Large animal (n=33) Total (n=48) 
Effect measure    
Odds ratio 10 (66.7) 20 (60.6) 30 (62.5) 
Odds ratio and 
regression 
coefficient 
1 (6.7) 2 (6.1) 3 (6.3) 
Prevalence odds 
ratio 
1 (6.7) 1 (3.0) 2 (4.2) 
Regression 
coefficient 
0 1 (3.0) 1 (2.1) 
Not applicable 0 3* (9.1) 3 (6.3) 
None reported 3 (20.0) 6 (18.2) 9 (18.8) 
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Table 7. Odds ratios and necessary assumptions by species type for manuscripts that included 
only incident cases and reported the odds ratios. 
 Small 
animal 
(n=9) 
Large 
animal 
(n=14) 
Total 
(n=23) 
Odds ratio 
may 
approximate 
Assumption 
needed 
Assumption 
stated 
Control sampling – 
fixed cohort 
      
End of 
follow-up 
2 1 3 Risk 
ratio 
Rare 
disease 
0 
Concurrently 0 1 1 Rate 
ratio 
Analysis 
matched 
on time 
1 
Beginning of 
follow-up 
0 0 0 Risk 
ratio 
Censoring 
unrelated 
to 
exposure 
0 
Unclear 0 1 1    
Control sampling – 
dynamic population 
      
Matched on 
time 
4 4 8 Rate 
ratio 
No 
further assumption 
needed 
 
Not matched 
on time 
2 6 8 Rate 
ratio 
Stable 
population 
0 
Unclear 
regarding 
time 
1 1 2 Rate 
ratio 
Stable 
population 
0 
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Abstract
Infectious bovine keratoconjunctivitis (IBK) is a common and important disease
of calves. Without e↵ective vaccines, antibiotic therapy is often implemented to
minimize the impact of IBK. This review updates a previously published system-
atic review regarding comparative e cacy for antibiotic treatments of IBK. Avail-
able years of CABI and MEDLINE databases were searched, including non-English
results. Also searched were the American Association of Bovine Practitioners and
World Buiatrics Congress conference proceedings from 1996-2016, reviews since 2013,
reference lists from relevant trials, and U.S. Food and Drug Administration New An-
imal Drug Application summaries. Eligible studies assessed antibiotic treatment of
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naturally-occurring IBK in calves randomly allocated to group at the individual level.
Outcomes of interest were clinical score, healing time, unhealed ulcer risk, and ulcer
surface area. A mixed-e↵ects model comparing active drug to placebo was employed
for all outcomes. Heterogeneity was assessed visually and using Cochranes Q-test.
Thirteen trials assessing nine treatments were included. Compared to placebo, most
antibiotic treatments were e↵ective. There was evidence that the treatment e↵ect dif-
fered by day of outcome measurement. Visually, the largest di↵erences were observed
7-14 days post-treatment. These results indicate improved IBK healing with many
antibiotics and suggest the need for randomized trials comparing di↵erent antibiotic
treatments.
Keywords: Antibiotics, infectious bovine keratoconjunctivitis, meta-analysis,
pinkeye, systematic review
1. Introduction
Rationale
Infectious bovine keratoconjunctivitis (IBK) or pinkeye is one of the most important
production-limiting diseases of pre-weaned beef calves. The clinical signs of IBK
include, lacrimation, photophobia, corneal edema, ocular pain, corneal ulceration,
and the potential for vision loss (Alexander, 2010). Calves with IBK lesions have
decreased weaning weight by 15-30 lb compared to una↵ected calves (Thrift & Over-
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field, 1974; Funk et al., 2009, 2014). Moraxella bovis is considered the primary causal
organism associated with IBK (George et al., 1984; Gould et al., 2013; Brown et al.,
1998). Moraxella bovoculi has also been suggested to play a role in IBK disease eti-
ology (Angelos et al., 2007). However, available evidence suggests prevention of IBK
with either commercially available or autogenous M. bovis or M. bovoculi vaccines is
ine↵ective (Funk et al., 2009) (Cullen et al., in press). In the absence of evidence sup-
porting an e↵ective IBK vaccine, antibiotic therapy is the best method for reducing
the production and welfare impacts of IBK. In 2006, members of our group published
a review of antibiotic treatments of IBK that included nine randomized controlled
trials (O’Connor et al., 2006). In that review, only one trial included an active-
to-active treatment comparison of di↵erent antibiotics and no antibiotic regime was
employed more than once. Therefore, in the prior review a pairwise meta-analysis
was not appropriate (O’Connor et al., 2006). Further, the 2006 review focused on
risk of unhealed corneal ulcers as the outcome. As ten years have passed since the
conduct of the initial review, it was decided to update the review and determine if
additional IBK treatment trials had been published in the ensuing decade that would
enable better understanding of comparative e cacy of antibiotic treatment options
for IBK. Additionally, statistical methods that allow for the comparison of multiple
treatments (mixed treatment meta-analyses, MTCMA) and methods that allow for
78
comparison of di↵erent outcomes (multivariate meta-analysis MVMA) have become
more accessible and it was thought these might enable better synthesis of the data
(Lu & Ades, 2004; Higgins & Whitehead, 1996; Jansen et al., 2008). Therefore, the
purpose of this systematic review was to update the previous review of antibiotics
available for IBK treatment (O’Connor et al., 2006) with all available relevant trials
and to conduct, if feasible, either a MTCMA or a MVMA to better understand the
comparative e cacy of antibiotic treatment options for IBK. The overall objective of
this review was to provide veterinarians and producers with information about the
comparative e cacy of antibiotic treatments for IBK in calves. Unlike the prior re-
view, treatment e cacy was measured using a variety of outcomes including clinical
ulcer score as described by the authors, duration until healing following antibiotic
treatment, cure risk based on authors’ definition of resolution of corneal ulcers, and
corneal ulcer surface area. A secondary outcome of interest was weight gain, either
total weight gain or average daily gain (ADG).
Methods
This manuscript was assembled using the PRISMA guidelines (Moher et al., 2009).
The PRISMA Checklist with corresponding section page numbers is available in the
supplemental materials.
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Protocol and registration
A protocol for the update was developed by four coauthors (JNC, JFC, CW, AOC).
The time-stamped protocol (21st Dec 2015) was submitted for record keeping to the
journal prior to starting the review, and any modifications that occurred after ap-
proval of the protocol are noted in the manuscript. The original protocol is available
in the supplemental materials.
Eligibility criteria i.e. the PICOS criteria
The review question was ”What is the comparative e cacy of antibiotics for the
treatment of IBK in beef and dairy cattle?” The eligibility criteria were defined in
terms of the population (P), intervention (I), comparator (C), outcomes (O) and
study design (S). The eligible population of interest (P) consisted of beef or dairy
cattle diagnosed with naturally occurring IBK. IBK diagnoses were defined either
by bacterial isolation of Moraxella spp., Neisseria spp., or Branhamella catarrhalis
(reclassified as Moraxella catarrhalis) or by the authors’ clinical definition when
bacterial isolation was not conducted. No restrictions were placed on the population
age, weight, or the country where the trial was conducted. Eligible interventions
(I) included any antibiotic treatment not banned for use in cattle and non-active
placebos. This restriction does not limit antibiotic interventions to those registered
for the treatment of IBK. Interventions banned for use were based on Group 1 and
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Group 2 lists from the Food Animal Residue Avoidance Databank (FARAD)a which
was consulted during the review process. Multidrug interventions (i.e. antibiotic
combined with anti-inflammatory component or antibiotic combined with antibiotic),
non-antibiotic treatments, vitamins, or homeopathic treatments were excluded as
not relevant to the review. The clarification to exclude vitamins or homeopathic
treatments was a protocol change. For example, if one arm of a three-arm trial treated
with penicillin plus dexamethasone, only the other two arms (penicillin and placebo)
were extracted. As multiple interventions were of interest, no specific comparator
(C) was specified.
The protocol initially defined the primary relevant outcome (O) as the incidence
of unhealed corneal lesions (or healed lesion) and the secondary relevant outcome
as measures of weight gain. However, the outcomes relevant to the review were
expanded during the review process to include clinical ulcer scores, duration until
ulcer healing, or corneal ulcer surface area. The rationale for this protocol change
and expansion was that many studies reporting relevant information included these
outcomes.
With respect to study design (S) characteristics, only randomized controlled trials
(RCT) that allocated calves at the individual level were considered relevant to the
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review. Trials must have been conducted under field conditions with naturally oc-
curring disease.
Information sources
All available years were searched in the Centre for Biosciences and Agriculture In-
ternational (CABI)b and MEDLINE R  c databases using the Iowa State University
Web of Science Interface. The proceedings table of contents from the last 20 years
(1996-2016) of the American Association of Bovine Practitioners (AABP) and World
Buiatrics Association were reviewed for potentially relevant conference abstracts.
The Food and Drug Administration (FDA) Freedom of Information (FOI) New An-
imal Drug Application (NADA) summaries databased was searched for IBK trial
data of approved cattle antibiotics. Searches of the Zoetise and Boehringer Ingel-
heimf websites were conducted to look for potentially relevant technical bulletins. We
searched these sites because Zoetis is the manufacturer of tulathromycin, a product
registered for treatment of IBK, and both companies make a non-generic injectable
oxytetracyline, another antibiotic for use to treat IBK. IBK reviews published after
2013 were also examined for relevant trials. After the completion of relevance screen-
ing, the bibliographies of relevant manuscripts were examined for trials meeting the
eligibility criteria.
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Search
The search strategy followed the general form of ”population” AND ”disease” AND
”intervention”. For MEDLINE R  ”Drug Therapy”, ”Injections”, and ”Anti-Bacterial
Agents” were searched as Medical Subject Headings (MeSH). For CABI, ”drug ther-
apy”, ”injection”, and ”antibacterial” were searched as Descriptors (DE). The search
strategy for CABI is presented in Table 1.
Study selection
The online systematic review software, DistillerSRg was used to manage all literature
records and associated data. The relevance assessment form was pilot tested by
two reviewers for approximately 20 manuscripts and modified to ensure agreement.
After establishing the final set of questions, the two reviewers independently read all
abstracts to identify potentially relevant manuscripts. One reviewer (JC) assessed
the proceedings table of contents from both conferences. Only one reviewer needed
to indicate potential relevance for the full text to be acquired. Full text manuscripts
were assessed by two reviewers for relevance. When two reviewers could not agree on
trial relevancy questions based on the full text, a third reviewer (AOC) would decide.
This decision was made as this reviewer is the most experienced with IBK. For trials
considered relevant by both reviewers or decided by the third reviewer (AOC), all
relevant data were extracted.
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Originally, we intended to only include manuscripts written in English. However,
a protocol modification was made such that manuscripts in languages other than
English were considered eligible. For foreign-language papers, we assessed the ab-
stract (if in English) and determined if there were reasons for exclusion based on
the above exclusion criteria (e.g. treatment combinations, banned treatment regi-
mens, non-random allocation, etc.). If it was not possible to exclude based on the
English abstract, we attempted to obtain the full text and where possible translated
the document using Google translate and again evaluated the text for exclusion-
ary evidence. PDF image files written in French, Italian, Spanish and Chinese that
could not be automatically translated were given to a single native speaker with a
background in statistics and study design to determine if the trials were random-
ized and contained at least two comparative groups. Therefore these papers did not
have two reviewers and were based on the judgement of the single native speaker.
Other foreign-language papers with PDF image files were excluded as were papers
that could not be obtained. Foreign-language theses were not translated and were
excluded.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
flow diagram was used as a template to present the study selection results (Moher
et al., 2009).
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Data extraction process
The data extraction process was pilot tested by two authors for a single outcome,
unhealed corneal ulcer risk (AOC and JNC). Upon inclusion of the other outcomes,
the form was modified to include all relevant outcome data. Data extraction was
completed from all eligible manuscripts by two reviewers independently. Extracted
data conflicts were resolved by a single author (JNC) in consultation with the orig-
inal manuscript data to ensure accuracy. When a trial was identified from multiple
sources, all sources were combined in order to obtain the most complete trial de-
scription.
Data items
Data extracted from each individual trial included: country in which the trial was
conducted, age and weight means or ranges of calves, included genders and breed,
concurrent management interventions (i.e. fly control or vaccinations), author defini-
tions of eligible IBK case and ”cured”, duration of observation period, cattle weights
pre- and post-treatment, whether random allocation based on IBK severity occurred,
dose and route of each intervention, number of unhealed corneal ulcers and total ul-
cer number per treatment, duration until healing, clinical scores, and corneal ulcer
surface area.
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For all continuous covariates and outcomes, standard deviations or standard errors
of the mean (SEM) were extracted. If the manuscript authors presented a standard
error it was converted to the standard deviation as this was a required input for
the statistical analyses (see below). The outcome data were extracted for each time
point reported when applicable. This protocol change was deemed necessary in or-
der to obtain su cient outcome data. When outcome data were presented only in
figures or plots, WebPlotDigitizer (version 3.9)h was used to digitize the figures in
order to extract relevant data. Plot digitizing was conducted in triplicate for contin-
uous outcomes per figure by a single reviewer (JC). If corneal ulcer surface area was
presented as square-root transformed, the data were back transformed to the raw
mean surface area and an approximate standard deviation to ensure the scales were
the same between studies (Jørgensen & Pedersen, 1998). This was accomplished as
follows:
x represents the square rooted value, then the mean value is defined as
mean =
n  1
n
(SDx)
2 + (meanx)
2
where (SDx) stands for the standard deviation of the squared rooted value, and
(meanx) stands for the mean value of the squared rooted value. The approximate
standard deviation was
SD = 2
 
SDx
p
mean
 
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To assess the accuracy of transformation, samples were randomly generated from
a normal distribution and the mean of x and the mean using the transformation
formula were compared. This procedure was repeated multiple times using di↵erent
random samples. The results were considered reasonable based on the opinion of one
author (CY). No statistical tests were utilized to compare predictions.
If authors reported only the percentage of unhealed corneal ulcers (calf or eye level),
counts were calculated based on the described arm’s sample size and rounded to the
nearest whole number. When continuous outcome data were presented in a stratified
manner (e.g. healing times for calves with moderate lesions versus severe lesions),
outcomes were combined using an appropriate statistical method (Higgins et al.,
2008). Similarly when discrete data were stratified by severity (i.e. unhealed corneal
ulcers for calves mild and moderate ulcers), counts were combined. When authors
reported outcomes on multiple days, all were extracted and the day of measurement
was recorded. Data that were presented for multiple location sites was extracted
separately per site.
Geometry of the network of studies
The geometry of the treatment network for each outcome were assessed using the
probability of interspecific encounter (PIE) index and C-score (Salanti et al., 2008).
The PIE index describes the network diversity where a value > 0.75, suggests the
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network has a relatively high diversity. The C-score test measures co-occurrence,
meaning particular intervention comparisons are more likely than others and a small
p-value indicates there exists statistically significant co-occurrence in the network.
PIE index was calculated by customer written R script (R Core Team, 2015) and
C score test was accomplished via R package EcoSimR (Gotelli et al., 2015) version
0.1.0.
Risk of bias within individual studies
Risk of bias was assessed at study level considering nature of the outcome (subjective
versus objective outcome) using the Cochrane Risk of Bias for trials (Higgins et al.,
2008). Two reviewers assessed each manuscript as ”high risk”, ”low risk”, or ”un-
clear risk” for selection, detection, attrition, reporting, and other potential sources
of bias. Disagreements as to the level of risk were discussed between three reviewers
(JNC, ST, and RD). If consensus could not be reached, unclear risk was chosen. For
the single foreign language paper that was considered relevant, the translator was
asked the risk of bias questions, the translator provided the answers and one of the
authors (AOC) made the risk of bias assessment. Manuscripts that described how
randomization was implemented (e.g. randomization schedule or by random number
draw) or randomization was stratified by clinical severity of IBK were considered low
risk for randomization. Allocation concealment was considered unclear risk unless
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the authors described sequential allocation to ensure even numbers between treat-
ment arms (high risk). Lack of caregiver blinding was considered unclear risk unless
treatment selectively caused a reaction in one treatment group and not the other. For
example one reviewer (ST) suggested that if application of an antibiotic caused eyelid
swelling in one treatment group, there were concerns that the a↵ected group may be
placed in one specific pasture over another. When blinding of outcome assessor was
not described, manuscripts were considered at low risk of bias if the outcome was
objective or assessed in an objective manner (e.g. fluorescein stain uptake) other-
wise for subjectvie outcomes they were considered at high risk of bias. Attrition bias
was considered unclear risk if outcome data were missing from the results without
author explanation. If less than 10% of outcome data were missing, attrition bias
was considered low risk. Selective reporting was considered to be associated with
a low risk of bias if all described outcomes were reported in the results, otherwise
the risk of bias was considered unclear. Additionally, pharmaceutical sponsorship
was considered for each included trial with extractable data. A study was considered
sponsored by a company if one of the authors was identified as being from a company
or the authors indicated a company as a funding source.
89
Summary measures
The summary measure for the incidence risk of unhealed corneal ulcers was the odds
ratio (OR) calculated from the log odds ratio. Data were organized such that the
non-active control arm would be the referent when calculating the odds ratio. In this
way an odds ratio less than one would indicate that the active treatment (numera-
tor) is more e↵ective than placebo (denominator). An odds ratio greater than one
would thus indicate that the placebo is more e↵ective than active treatment. For
clinical scores, the standardized mean di↵erence was the principal summary mea-
sure. The standardized mean di↵erence (SMD) was chosen to account for di↵erent
scales employed between manuscripts. For all other outcomes (duration until heal-
ing and corneal ulcer surface area), the mean di↵erence was the principal summary
measure. Duration until healing and ulcer surface area (following appropriate trans-
formation as described above) are on the same scales, respectively, thus the summary
measure is a more interpretable e↵ect size. When calculating the SMD and mean
di↵erence, active treatment is subtracted from placebo. Therefore a positive mean
di↵erence implies that the placebo had a higher mean than the intervention group.
As lower levels of clinical score, shorter healing time, or smaller ulcer surface area
imply improved healing, positive mean di↵erence implies the intervention is better.
For example, if calves that received placebo had on average higher clinical scores (i.e.
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more severely a↵ected eyes) than calves receiving active treatment, the SMD would
be greater than zero. Similarly, if calves that received placebo had on average larger
corneal ulcer surface areas than calves receiving active treatment, the risk di↵erence
would be greater than zero.
Planned method of statistical analysis - pairwise meta-analysis
Pairwise meta-analyses were conducted for each outcome separately for trials that
included a non-active control arm. Meta-analyses of active-to-active comparisons
were not conducted due to the lack of trials assessing the same intervention. The
meta-analyses were conducted using the R package metafor and the rma function
using the default restricted maximum likelihood estimation method (Viechtbauer,
2010). The rma function requires data in the form of an e↵ect size and variance for
continuous outcomes and count data for dichotomous outcomes. The escalc function
was used to generate this data for all analyses (Viechtbauer, 2010). For calculating
the log odds ratio (unhealed ulcer risk), a continuity correction of 0.5 was included
and added to each cell for instances when a cell within a ”2 X 2” table contained
zero. A nested multilevel structure which included a fixed e↵ect for measurement
day nested within a random e↵ect for trial was employed. The compound symmetry
covariance structure was used to account for repeated measures within a single trial.
This model structure was considered appropriate since outcome data from the same
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population assessed on multiple days should be correlated within each trial. The
pairwise model equation for the log odds ratio and standardized mean di↵erence was
as follows:
Let yst stands for the observed e↵ect size in the s-th study at time point t, where s =
1, 2, · · · , n, t = 1, 2, · · · ,ms. n is the number of studies with a particular outcome,
and ms is the total number of time points in study s. Let ys = (ys1, · · · , ysms)T
ys ⇠ N(µ,⌃ms⇤ms)
where variance covariance matrix ⌃ms⇤ms follows compound symmetric structure:
⌃ms⇤ms =  
2
0BBBBBBBBBB@
1 ⇢ · · · ⇢
⇢ 1 · · · ⇢
· · · · · · · · · · · ·
· · · · · · · · · 1
1CCCCCCCCCCA
Summary e↵ects were calculated as active treatment subgroups, all of which were
compared to a non-active arm. We presented the data on forest plots for ease of
interpretation; however we did not present summary e↵ect sizes across the active
treatment subgroups as these would be meaningless.
We assessed heterogeneity when more than one study or time point within a study
was available for a comparison of interest. When this occurred we used Cochrane’s Q
homogeneity test. Cochrane’s Q tests the null hypothesis that the observed treatment
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e↵ect between trials or repeated measures within a trial are equivalent at statistical
threshold ↵ (Tate & Brown, 1970).
Risk of bias assessment
We did not conduct an analysis for small size e↵ect across the studies as there was
an insu cient number of studies for either a meaningful visual interpretation or a
statistical analysis (Sterne et al., 2011).
Ancillary analysis
The expectation was that a number of included trials would have provided calf weight
data before and after treatment. This weight data (total weight gain or ADG) would
have allowed for pairwise analyses and summary measures at least for active to non-
active comparisons. A mixed treatment comparison meta-analysis was planned based
on the a priori belief that a suitable number of trials fitting our inclusion criteria
would be recovered from the literature search.
Results
Study selection
The search results are presented in Figure 1. The citation database searches were
completed on December 21, 2015. The FDA FOI NADA summaries contained 23
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potentially relevant summaries based on the search of ”infectious bovine kerato-
conjunctivitis”. Fourteen manuscripts described reviews and were set aside to be
examined later if published in the last three years. The list of full texts assessed and
the first reason for exclusion based on the order of questioning in the screening forms
are provided in the supplemental material.
No additional relevant manuscripts were identified (that were available through an
inter-library loan system) from recent IBK reviews, reference lists from the full text
relevant manuscripts, or the last 20 years of AABP proceedings. Nine of the last
ten World Buiatrics Association conference proceedings were assessed for potentially
relevant trials. One conference proceedings (2010 World Buiatrics Congress) could
not be examined as the holding library declined to loan the requested materials. One
relevant randomized trial was identified from the 1998 proceedings (Cosgrove et al.,
1998).
Study characteristics
Of the 97 manuscripts, 16 were trials that described randomization to treatment
arm and were included for data extraction. Thus the conference proceedings and
database searches combined resulted in a total of 17 relevant trials. The trial from
the conference proceedings could not be extracted as the authors did not report
the number of calves allocated to each treatment arm (Cosgrove et al., 1998). One
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manuscript could not be extracted because measures of variation for the reported
outcome, clinical eye score, were not reported (Roeder et al., 1995). No data from an
additional manuscript could be extracted as the authors only reported comparative
e cacy for healing time without measures of variation (Edmondson et al., 1989). A
Spanish language trial could not be extracted because the authors did not report the
number of calves allocated per treatment arm (Abdala et al., 2002). Thus from the
17 manuscripts, 13 contained data suitable for extraction (George et al., 1988, 1989;
Chadli, 1992; Allen et al., 1995; Eastman et al., 1998; Angelos et al., 2000; Gokce
et al., 2002; Zielinski et al., 2002; Dueger et al., 2004; Starke et al., 2007; Senturk
et al., 2007; Freedom of Information Summary, 2007; Quesada et al., 2010).Author
definitions of the outcomes are included in the supplemental material.
Table 2 and Table 3 provide the population and study characteristics of each manuscript
for which data were extracted. Since the original systematic review in 2006, four new
randomized trials have been published (Starke et al., 2007; Senturk et al., 2007; Free-
dom of Information Summary, 2007; Quesada et al., 2010). One of the four trials
was only available in French (Senturk et al., 2007) and one was an FDA drug ap-
plication (Freedom of Information Summary, 2007). The drug application results
were also published as a technical bulletin found by one of the reviewers (JFC) and
available on the manufacturer websitee (Pfizer Animal Health, 2008). One trial was
95
published in 2002 (Gokce et al., 2002) but was incorrectly excluded from the original
systematic review. Concurrent management interventions were rarely reported and
thus not included in the descriptive results.
Although 13 randomized trials had at least some extractable outcome data, this did
not mean all the outcomes measured and reported by all 13 trials could be extracted.
For some studies, unhealed corneal ulcer data could not be extracted because the
study population contained both a↵ected and una↵ected calves (George et al., 1988;
Eastman et al., 1998) or because the figure contained treatment arms combined for
calves diagnosed with IBK (Starke et al., 2007). For another paper, the image reso-
lution was too low to extract ulcer surface area data beyond days 3-4 (Dueger et al.,
2004) Clinical score data could not be extracted because the population contained
both a↵ected and una↵ected calves (George et al., 1988) or authors did not provide
any measures of variation (Allen et al., 1995; Zielinski et al., 2002). Ulcer surface
area data could not be extracted due to the population containing both a↵ected and
una↵ected calves (George et al., 1988). For three manuscripts, healing time data
could not be extracted as the authors did not provide any variance measures but
only a range (Angelos et al., 2000; Freedom of Information Summary, 2007; Quesada
et al., 2010).
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Summary of the treatment network geometry
The network of treatment comparisons for each outcome is presented in Figure 2.
With the exception of the unhealed ulcers network, we observed a general lack of
available comparisons suitable for a MTC meta-analysis. Specifically, very few trials
of the same intervention were available. A multivariate meta-analysis was also not
possible due to the overall lack of multiple common treatment comparisons across
outcomes.
Analysis of the treatment network geometry
For the outcome clinical score, the probability of interspecific encounter (PIE) index
was 0.79, the C-score was 1.20 with an associated p-value of 0.86.
For the outcome healing time, the PIE index was 0.85, the C-score was 1.20 with an
associated p-value of 0.14.
For the outcome risk of unhealed ulcers, the PIE index was 0.86, the C-score was
1.88 with an associated p-value of 0.81.
For the surface area outcome, the PIE index was 0.78, the C-score was 1.20 with
p-value is 0.93.
The PIE index was greater than > 0.75 for all four outcomes suggesting relatively
high network diversity. This is not surprising as the 13 studies did represent di↵erent
interventions. None of the C-score p-values were significant meaning co-occurrence
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is not occurring within the four outcome networks. These results may reflect the fact
that multiple studies on the same intervention rarely occurred in this dataset and
may also be due to the smaller number of trials available.
Risk of bias within studies
Risk of bias for each study are presented in Figure 3. The main concerns for bias
were insu cient descriptions of randomization. No manuscripts in our sample set de-
scribed concealment of the allocation sequence. It should be noted that although all
studies were included based on randomization, one study (Zielinski et al., 2002) was
included in the meta-analysis as a randomized trial because the authors self described
the paper as a randomized block design however it was considered high risk by the
reviewers for selection bias due to a description of sequential allocation. However
as other papers were not required to prove random allocation by documenting the
method of allocation, it was decided to retain the paper and consider it randomized.
The risk of bias assessment resulted in a fairly large number of unclear risk assess-
ments. This was due to the fact that these biases are often di cult to assess in older
papers that frequently do not report in a manner consistent with recent recommen-
dations such as the REFLECT guidelines (O’Connor et al., 2010).
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Synthesis of pairwise meta-analysis of active treatments compared to placebo and
exploration of heterogeneity
For presentation of the data, we grouped drugs together by compound and ignored
the route of dose as there were insu cient data for further refining the treatment
protocol.
Clinical score as outcome
Figure 4 contains the summary SMD for the comparison of active treatments to
non-active treatments. Notice that each antibiotic only has data from a single
study assessed at multiple time points. The SMD and 95% confidence interval
(95% CI) for cloxacillin 0.71 (0.51, 0.91), florfenicol 0.70 (0.52, 0.87), and clindamycin
3.37 (2.78, 3.96) suggest lower clinical scores (i.e. treatment successful) in calves as-
signed to active treatments compared to non-active treatment.
For clinical score there was no evidence of heterogeneity within the studies for each
antibiotic. It should be noted that normally in meta-analysis heterogeneity assess-
ment aims to assess across studies, but in this analysis the comparison is across
time points within each study. The Q test statistic was 1.8 with p-value 0.99 for
cloxacillin, 0.58 with p-value 0.99 for florfenicol, and 1.5 with p-value 0.48 for clin-
damycin. These Q statistics and associated p-values suggest insu cient evidence to
reject the null hypothesis of homogeneity (Hoaglin, 2016).
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Healing time as outcome
The durations until corneal ulcer healing are presented in Figure 5. Healing time was
the only outcome that contained e↵ect measures for the same active to non-active
comparison from more than one trial (Allen et al., 1995; Eastman et al., 1998). These
studies assessed 300,000 IU of penicillin administered into the subconjunctiva. The
mean di↵erence (MD) and 95% CI for penicillin 3.23 ( 5.85, 12.31) and cloxacillin
2.34 (0.28, 4.40) indicate active treatment reduces healing time compared to placebo.
However for the penicillin subgroup one trial suggested penicillin was ine↵ective based
on the point estimate and confidence interval (Allen et al., 1995). This di↵erence in
estimates across the studies for penicillin is reflected in the test for heterogeneity.
The Q test statistic was 9.1 with p-value 0.0026 for penicillin and 0.057 with p-value
0.81 for cloxacillin.
Unhealed corneal ulcers as outcome
The results of the pairwise meta-analysis for unhealed corneal ulcers by active treat-
ment subgroup are presented in Figure 6. Compared to non-active arms, odds ratios
(95% CI) from the random e↵ects models were as follows, penicillin 0.19 (0.12, 0.30),
florfenicol 0.092 (0.027, 0.31), tilmicosin 0.36 (0.19, 0.69), tulathromycin 0.13 (0.085, 0.21),
and ceftiofur 0.35 (0.20, 0.63). These results suggest, as expected, active treatment
is overall more e↵ective than no treatment. A summary e↵ect was not calculated
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for the oxytetracycline subgroup as only one arm of one trial used oxytetracycline to
treat IBK (Zielinski et al., 2002).
The Q test statistic was 9.8 with p-value 0.45 for penicillin, 1.1 with p-value 0.29
for florfenicol, 0.024 with p-value 1 for tilmicosin, 25 with p-value 0.0035 for tu-
lathromycin, and 3.8 with p-value 0.58 for ceftiofur.
Corneal ulcer surface as outcome
Figure 7 displays the summary MD for each active to non-active subgroup. The MD
and 95% CI for cloxacillin 0.17 (0.11, 0.24), florfenicol 1.62 (1.22, 2.01), and ceftiofur
0.096 (0.066, 0.13) suggest active treatment results in smaller corneal ulcer surface
areas compared to placebo. The summary MD for penicillin  0.34 ( 0.48, 0.19)
would suggest non-treatment reduces corneal ulcer size more e↵ectively than treat-
ment with penicillin in this trial population.
The Q test statistic was 5.6 with p-value 0.78 for cloxacillin, 12 with p-value 0.04
for florfenicol, 13 with p-value 0.038 for ceftiofur, and 6.6 with p-value 0.086 for
penicillin.
Assessing sources of systematic bias
The typical sources of systematic bias are a lack of randomization, outcome blind-
ing, and trial sponsorship. Our dataset included only randomized trials, 7 of which
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employed random allocation stratified by IBK severity, 6 described blinding of out-
come(s), and 5 were pharmaceutical company sponsored. To assess risk of bias across
studies, it is necessary to have multiple studies of the same intervention; however the
sparse data in this data set precluded such an analysis. We were therefore unable to
assess these methodological variables further beyond reporting the numbers here.
The rationale for not assessing bias due to caregiver blinding is that no studies
reported this process, so it could not be assessed. Loss-to-follow-up was also not
assessed because it was not possible to accurately determine, due to the approach to
reporting if authors made the decision a priori to only report for animals that com-
pleted the study. Any assessment of loss-to-follow-up would be inaccurate, highly
subjective and likely meaningless. These decisions were made while the protocol was
being developed, and should have been included in the protocol but were not.
Risk of bias across studies
The sample set did not contain multiple trials comparing the same active treatment
for one of the four outcomes thus we did not examine funnel plots. Only for duration
until ulcer healing comparing penicillin to placebo was there more than one trial
(Allen et al., 1995; Eastman et al., 1998).
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Active-to-active comparisons of interest
As can be seen from the networks, only three studies assessing active to active com-
parisons have been conducted that did not just use di↵erent doses or routes of the
same drugs. Gokce et al. (Gokce et al., 2002) reported that florfenicol was more
e↵ective than oxytetracycline for healing time [MD=5.42 and 95% CI (-7.98, 18.82)
extra days until healing for oxytetracycline] and lower risk of unhealed ulcer by
day 28 [OR=0.05 and 95% CI (0.00, 1.00) - oxytetracycline as the referent]. For
risk of unhealed ulcer, Chadli (Chadli, 1992) indicated oxytetracycline was more ef-
fective than aureomycin [OR=17.26 (5.43, 54.86) - oxytetracycline as the referent].
Zielinski et al. (Zielinski et al., 2002) suggested that tilmicosin was more e↵ective
at multiple doses than oxytetracycline. For example an OR of 0.18 (0.044, 0.76)
at day 21 was observed when comparing 300 mg of either antibiotic administered
sub-subconjunctivally.
Mixed treatment comparisons meta-analysis
Based on the small sample size of randomized trials with extractable data, the MTC
meta-analysis failed to produce interpretable results. We did conduct the analysis
for the most commonly measured outcome, unhealed ulcers, which had the largest
network. However, for the resulting ranking of treatment analysis all active treat-
ments and even placebo had overlapping credibility intervals around 0-11 (data not
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shown). This was likely due to the relatively close e↵ect measure estimates and lack
of enough available trial data to distinguish between treatment e cacies. As a re-
sult the MTC meta-analysis was not investigated further or reported further. We
also considered conducting a multivariable meta-analysis which would enable us to
borrow information across outcomes, but the data were too sparse to even attempt
such an analysis.
Ancillary analysis - IBK e↵ect on weight
As it has been previously observed that IBK-a↵ected calves have decreased weaning
weight compared to una↵ected herd mates (Thrift & Overfield, 1974; Funk et al.,
2009; O’Connor et al., 2011; Funk et al., 2014), the expectation was that a number
of trials would include ADG or final weight. However of the included trials, only
two manuscripts reported weight as an outcome (Zielinski et al., 2002; Roeder et al.,
1995). Additionally the authors of one of the two manuscripts did not report mea-
sures of variance for final weight or ADG and therefore the data cannot be used
(Zielinski et al., 2002). As a result ancillary analysis was not conducted.
Discussion
This systematic review update identified 17 randomized trials, 13 of which had data
that could be extracted. Four of the 13 were published since the last review in
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2006. This review expanded the outcomes of interest to include not only risk of
unhealed ulcers but also clinical scores, duration until healing, and ulcer surface
area. With the exception of oxytetracycline for unhealed ulcer risk and penicillin for
ulcer surface area, the results indicate that overall any active intervention is more
e↵ective than placebo for the treatment of IBK in cattle. This result was observed
for all assessed outcomes and should be expected. Unfortunately we were not able
to conduct a meaningful mixed treatment analysis that would provide additional
information about the comparative e cacy of the drugs because of the sparse data
for each intervention. We had initially proposed to conduct a mixed treatment
comparison that would use direct and indirect information to provide information of
the comparative e cacy of the active drugs. With so few trials reporting active to
active comparisons this would provide critical information for treatment selection.
Of particular interest were the sideways parabola-type shapes produced from lining
up the e↵ect measures for each day within an active treatment subgroup. For example
the cloxacillin results from the ulcer surface area forest plot (Figure 7), appear as
two (one for 250 mg and one for 375 mg) sideways parabolas starting around the
null (zero) at day four, bending away from the null, and returning back by day 16.
Although not necessarily statistically relevant based on the confidence intervals, the
greatest e↵ect size point estimate (or the furthest from the null on the parabola)
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was observed on day seven or day ten depending on the dose. These results suggest
that the best time in which to observe a di↵erence between treatments using surface
area as an outcome should be between day 7-10, and that beyond day 16 the choice
of an active antibiotic intervention or placebo makes no di↵erence. Similar shapes
were observed for ceftiofur, florfenicol (largest observed e↵ect size at day seven or
day 14), tulathromycin, and penicillin. For the penicillin subgroup however the
parabola is orientated in the other direction indicating penicillin made no impact
on surface area. Considering our summary measures are compared to placebo, we
would expect the di↵erence to be even smaller for trials comparing active-to-active
treatments. Although to a lesser extent, similar shapes were observed for some of
the active treatment subgroups for the clinical score (Figure 4) and unhealed ulcer
risk (Figure 6) forest plots.
By using multiple time points from within the same studies for our summary mea-
sures, we expected the Q statistic and p-value to indicate heterogeneity. This is due
to IBK self-healing without the application of antibiotics and producing the side-
ways parabolas. For healing time (penicillin), unhealed ulcer risk (tilmicosin and
tulathromycin), and the surface area (florfenicol and ceftiofur) outcomes, the null
hypothesis of homogeneous e↵ect measures across days was rejected at an ↵ of 0.05
within active subgroups.
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One of the reasons for conducting an MTC meta-analysis is to make active-to-active
treatment comparison e cacy predictions that do not exist as publicly available data.
These comparison predictions allow for the ranking of treatments by e↵ectiveness
which ultimately enable the clinician to make the best treatment decision for their
clients and patients. In the absence of a suitably large enough trial data set, this
type of meta-analysis is not possible. As this systematic review demonstrated, this
is exactly the case for the antibiotic treatment of IBK. In these circumstances the
clinician should use whatever available active-to-active data that exists realizing
there is more variability based on the one or two estimates as they are single random
events.
We found only one study that made this direct comparison at a single time point (28
days). That trial compared 20 mg/kg IM oxytetracycline to 20 mg/kg IM florfenicol
using unhealed ulcer risk as the outcome (Gokce et al., 2002). The results suggested
florfenicol was superior (OR=0.05). This single observation suggests florfenicol might
be more e↵ective than oxytetracycline. However, this does not mean that florfeni-
col should be the treatment of choice, as comparative e cacy is only one factor in
treatment decisions. Interestingly only oxytetracyline and tulathromycin are regis-
tered for use for IBK in the US. We could not find any peer-reviewed studies of the
e cacy of tulathromycin that met our PICOS criteria [one trial published in Ital-
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ian did not have a valid comparator (Emarcora et al., 2010) and one trial employed
a challenge model (Lane et al., 2006)]. The only data we have for this treatment
option is from the FDA FOI NADA summary (Freedom of Information Summary,
2007) and a technical bulletin from the manufacturer website (Pfizer Animal Health,
2008). These are not places we would expect many producers or veterinarians to
look for information about e cacy. In Canada florfenicol is also registered for use
for treatment of IBK, but we could not find the equivalent of the FDA NADA FOI
for this use.
In summary, the results of this systematic review and meta-analysis strongly indicate
that antibiotics of many kinds improve healing compared to placebo. The trial results
also suggest a need for more active-to-active randomized trials in the treatment of
IBK in calves. Finally, the maximum power of those studies to detect di↵erences
between treatments is perhaps around 7 to 14 days post treatment.
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4. Tables
Table 1: Database search terms for the Centre for Biosciences and Agriculture Internatinal (CABI)
and MEDLINE databases.
Population AND Disease AND Intervention
TS=(beef OR bovine OR calf OR calves OR cat-
tle OR cow OR dairy OR angus OR hereford OR
holstein OR ruminant OR steer)
TS= (keratoconjunctivitis OR conjunctivitis OR
pink eye OR pinkeye OR IBK OR Branhamella OR
Moraxella OR Mycoplasma bovoculi OR Neisseria)
TS = (antibiotic OR antimicrobial OR amoxi-
cillin OR ampicillin OR ceftiofur OR chlortetra-
cycline OR cloxacillin OR danofloxacin OR en-
rofloxacin OR erythromycin OR florfenicol OR
gamithromycin OR gentamicin OR lincomycin OR
oxytetracycline OR penicillin OR spectinomycin
OR sulfadimethoxine OR sulfamethoxazole OR
tetracycline OR tildipirosin OR tilmicosin OR
trimethoprim OR tulathromycin OR tylosin) OR
DE= (drug therapy OR injection OR antibacterial
agents)
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Table 2: Population characteristics for each extractable trial. Weight presented as a range or +/-
the SD.
Author Publication
year
Population Number
of sites
Relevant
arms
George et al. 1988 USA, Hereford, m/f, 146-312kg, 6 months 1 2
George et al. 1989 USA, Holstein (Trial I), Angus cross (Trial II),
m/f, 2-9 months
2 4
Chadlin, M. 1992 Morocco 2
Allen et al. 1995 USA, Angus and Hereford, f, 6-8 months 1 2
Eastman et al. 1998 USA, Hereford, 6 months 1 2
Angelos et al. 2000 USA, Angus, Angus-Hereford, Holstein, m/f,
125.9-364.5 kg, 4-12 months
4 3
Zielinski et al. 2002 Argentina, Hereford, m, 6 months 1 6
Gokce et al. 2002 Turkey, Swiss Brown, 6-12 months 1 2
Dueger et al. 2004 USA, Angus-Hereford (SFS), Holstein (CD),
3-9 months
2 2
Starke et al. 2007 Country not reported, Holstein, m, 119 +/- 25
kg
1 2
Senturk et al. 2007 Turkey, Holstein, 4-28 months 1 2
FOI Summary
NADA 141-244
2007 USA, 138 to 342 kg and 4-10 months (WI site),
156 to 395 kg and 6-14 months (CA site)
2 2
Quesada et al. 2010 Country not reported, f, 326 +/- 15.8 kg 1 2
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Table 3: Trial characteristics for each extractable trial. IM = intramuscular, SC = subcutaneous, SJ = subconjunctival, TOP =
topical opthalmic.
Author Publication
year
Duration of ob-
servation
Treatment (size per arm) Extractable outcomes Blinding Stratification by
severity
Sponsorhip
George et al. 1988 54 days non active (n=52), oxytetracycline 20 mg/kg IM (n=52) healing time no no yes
George et al. 1989 16 days non active (Trial I n=20), cloxacillin 250 mg TOP (Trial
I n=23, Trial II n=8), cloxacillin 375 mg TOP (Trial I
n=21, Trial II n=8)
surface area, clin score,
heal time
yes no no
Chadlin, M. 1992 15 days aureomycin 1% wash TOP (n=53), oxytetracycline 1
ml/10 kg IM (n=53)
unhealed risk no not translated not translated
Allen et al. 1995 84 days non active (n=14), penicillin 300,000 U SJ (n=18) surface area, healing
time
yes yes no
Eastman et al. 1998 49 days non active (n=39), penicillin 300,000 U SJ (n=38) unhealed risk, healing
time
no yes no
Angelos et al. 2000 20 days non active (n=52), florfenicol 20 mg/kg IM (n=49), flor-
fenicol 40 mg/kg SC (n=41)
unhealed risk, surface
area, clin score
yes yes yes
Zielinski et al. 2002 21 days non active (n=19), oxytetracycline 300 mg SJ (n=20),
tilmicosin at 2.5 mg SC (n=20), 5 mg SC (n=21), 10 mg
SC (n=20), and 300 mg SJ (n=19)
unhealed risk yes yes yes
Gokce et al. 2002 70 days florfenicol 20 mg/kg IM (n=15), oxytetracycline 20
mg/kg IM (n=15)
unhealed risk, healing
time
no no no
Dueger et al. 2004 21 days non active (Site I n=40, Site II n=26), ceftiofur 6.6 mg/kg
SC (Site I n=38, Site II n=26)
unheal risk, surface
area
yes yes yes
Starke et al. 2007 108 days oxytetracycline 20 mg/kg IM (n=27), oxytetracycline 200
mg SJ (n=29)
healing time no yes no
Senturk et al. 2007 15 days non active (n=18), clindamycin 150 mg SJ (n=18) clin score no no no
FOI Summary NADA
141-244
2007 21 days non active (n=49 at CA site, n=49 at WI site), tu-
lathromycin 2.5 mg/kg SC (n=50 at CA site, n=50 at
WI site)
unhealed risk no yes yes
Quesada et al. 2010 21 days florenicol 20 mg/kg IM (n=20), florfenicol 126
mg/bovine/week TOP (n=21)
unhealed risk yes no no
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5. Illustrations
Figure 1: Flow chart illustrating the database searches and manuscript exclusions during the screen-
ing and data extraction processes.
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Clinical Score
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Unhealed Ulcers
Figure 2: Network of treatment arms for each outcome. The size of the node and line width
represent the relative number of arms and direct comparisons, respectively. IM = intramuscular,
SC = subcutaneous, SJ = subconjunctival, TOP = topical opthhalmic, aureo = aureomycin, ceft
= ceftiofur, clind = clindamycin, clox = cloxacillin, flor = florfenicol, oxytet = oxytetracycline, pen
= penicillin, tilm = tilmicosin, tula = tulathromycin.
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Figure 3: Risk of bias per manuscript for which data were extracted. Low risk is indicated by green,
high risk by red, and unclear risk is blank.
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Figure 4: Standardized mean di↵erence (SMD) for clinical score - all available pairwise treatments
that included a non-active arm.
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Figure 5: Mean di↵erence for healing time - all available pairwise treatments that included a non-
active arm.
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Figure 6: Odds ratio for unhealed corneal ulcers - all available pairwise treatments that included a
non-active arm.
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Figure 7: Mean di↵erence for surface area - all available pairwise treatments that included a non-
active arm.
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CHAPTER 5. GENERAL CONCLUSIONS 
General Discussion 
Overall, the results of this thesis indicate that important study design considerations or 
characteristics are often lacking if not entirely unknown from a number of RCTs and case-
control studies in the veterinary science. Specifically, the case-control survey suggested there is a 
fair amount of confusion as to the conduct of this deceptively simple study design. From our 
sample, nearly 40% of studies that assessed a disease etiology failed to sample study subjects on 
the basis of an outcome – the defining feature of the case-control design. Moreover no studies 
reported additional design features that would enable a more interpretable outcome. The 
systematic review and meta-analysis did not fair much better with regards to the implementation 
and reporting of key design features of RCTs. From roughly 100 manuscripts examined for 
relevance in the systematic review, less than 20% randomized subject to treatment. Of the trials 
that reported the most basic of design and statistical considerations (e.g. numbers allocated to 
treatment arms, measures of variation provided), less than half reported the blinding of outcome 
assessment. Randomization and blinding of outcome assessment are typically fundamental 
aspect of a well-conducted RCT. 
Failure to implement and thoughtfully report all design and analysis aspects of any 
research study have major implications: 1) the ability to make an accurate and valid inference 
may be hindered, 2) proper explanation of a more interpretable effect measure may be 
squandered, 3) misidentification of the “true” study design could lead to exclusion from 
systematic reviews resulting in the loss of potentially valuable data, and 4) perpetuate unsuitable 
or incorrect study design descriptions in the veterinary literature at large.  
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Recommendations for Future Work 
The results and implications of this thesis suggest the need for multiple streams of future 
work and research. Firstly, based on the results of the case-control survey, it is highly likely 
similar misconceptions are occurring in other study designs within the veterinary science. Thus a 
similar or even more expansive examination of the other observational study designs (e.g. cohort, 
cross-sectional) would be of value. This is especially true of the cohort design as this 
observational design is sometimes included in systematic reviews and meta-analyses. More 
investigations into what is occurring with these design choices in the veterinary science may lead 
to the development of veterinary specific guidelines for the reporting of studies. Ultimately this 
will benefit improved animal health through valid inference and accurate research synthesis. 
Secondly, as a result of the propensity amongst clinicians in choosing the case-control design to 
efficiently examine a disease etiology, in-depth training and teaching of the case-control design 
is crucial in maximizing the inferential value of the research. As mentioned in the discussion of 
Chapter III, perhaps a more effective way in which to teach observational study design is to 
employ a simpler classification system that rejects directionality as a foundation. Finally, 
additional research is needed to determine how to properly include effect measures where the 
design considerations suggest a more interpretable and attractive estimation is possible. 
